Functional Interactions Between Par-1b Protein Kinase and RNF41 E3 Ubiquitin Ligase by Vega, Katherine Terese
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
9-1-2012
Functional Interactions Between Par-1b Protein
Kinase and RNF41 E3 Ubiquitin Ligase
Katherine Terese Vega
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Vega, Katherine Terese, "Functional Interactions Between Par-1b Protein Kinase and RNF41 E3 Ubiquitin Ligase" (2012). All Theses
and Dissertations (ETDs). 985.
https://openscholarship.wustl.edu/etd/985
WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Biochemistry 
 
 
Dissertation Examination Committee: 
 
Helen Piwnica-Worms, Chair 
Phyllis Hanson 
Greg Longmore 
Linda Pike 
Jason Weber 
Zhongsheng You 
 
 
 
Functional Interactions Between Par-1b Protein Kinase and RNF41 E3 Ubiquitin Ligase 
 
 
 
By 
Katherine Terese Vega 
 
 
 
 
 
 
 
 
A dissertation presented to the  
Graduate School of Arts and Sciences 
 of Washington University in  
partial fulfillment of the 
 requirements for the degree 
 of Doctor of Philosophy 
 
August 2012 
 
Saint Louis, Missouri 
 
 
 
 
 
  -ii- 
 
ABSTRACT OF THE DISSERTATION 
Functional Interactions Between Par-1b Protein Kinase and RNF41 E3 Ubiquitin Ligase 
By 
Katherine Terese Vega 
Doctor of Philosophy in Biology and Biomedical Sciences 
 (Biochemistry) 
Washington University in St. Louis, 2012 
Professor Helen Piwnica-Worms 
 
The Par-1 family of serine/threonine protein kinases functions to regulate cell polarity 
and is conserved from yeast to humans. Par-1 is encoded by one of six Par (partitioning-
defective) genes (Par-1-6) originally identified in a genetic screen conducted in 
Caenorhabditis elegans (C. elegans).  The mammalian Par-1 family is comprised of four 
members (Par-1a, b, c and d).  Par-1 kinases are regulated by two arms of the Protein 
Kinase C (PKC) pathway.  Atypical Protein Kinase C (aPKC) phosphorylates Par-1b on a 
conserved threonine residue (T595) and I participated in studies demonstrating that novel 
Protein Kinase C (nPKC) activates Protein Kinase D (PKD) to directly phosphorylate 
Par-1b on serine 400 (S400), a residue that is conserved in all four mammalian Par-1 
kinases as well as the fly ortholog.  Phosphorylation of Par-1b on T595 and S400 causes 
Par-1b to relocate from membranes to the cytosol and to bind 14-3-3 proteins.  In 2004, 
Brajenovic, et al. reported the results of a study that used tandem affinity purification 
(TAP) to isolate human Par-1d along with associated proteins.  Nrdp1/RNF41, a RING 
finger E3 ligase was identified in their screen along with 14-3-3 and aPKC.  I found that 
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Par-1b binds to RNF41 and I identified RNF41 as a novel cell polarity determinant.  My 
work demonstrated that phosphorylation of RNF41 on S254 by Par-1b is necessary for 
establishing epithelial cell polarity. 
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Introduction 
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The Par proteins in development and disease 
 The Par proteins are important for establishing cell polarity in the embryo and are 
found to play crucial roles in a variety of human diseases.  In the Caenorhabditis elegans 
(C. elegans) embryo the Par proteins are required for asymmetric cell division of the 
embryo (Kemphues et al., 1988) and in epithelial cells for the establishment of apical-
basal cell polarity (Rodriguez-Boulan and Nelson, 1989).  In mice, Par-1b (one of the 
Par-1 mammalian orthologs) has been show to be important for fertility, immune 
homeostasis, learning, and memory as well as glucose metabolism(Hurov et al., 2007).  It 
has been suggested that epithelial cell polarity may exert a tumor suppressive function in 
mammals through its participation in the establishment and maintenance of the 3D 
organization of epithelial tissues as a whole.  Par-1, a serine/threonine protein kinase, is 
phosphorylated and activated by the Par-4 (LKB1) tumor suppressor (Fig. 1.3) and LKB1 
is mutated in Peutz-Jeghers cancer syndrome (PJS) (Baas et al., 2004b).  It is important to 
note that a common theme in establishing and maintaining cell polarity is the antagonistic 
relationship between the Par proteins through the addition of posttranslational 
modifications such as phosphorylation.  Moreover, phosphorylation of Par proteins also 
affects protein-protein interactions.  
The par genes and Par proteins: Asymmetric localization and fundamental for cell 
polarization 
 The par genes are required for asymmetric cell division of the C. elegans embryo 
into two daughter cells (Kemphues et al., 1988) and epithelial cells depend on the 
asymmetric organization of cellular components along their apical-basal axes.  It is the 
activity of asymmetrically localized proteins and protein complexes that regulate this 
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polarity (Rodriguez-Boulan and Nelson, 1989).  Par-1 is one of six par (partitioning-
defective) genes (Par-1, Par-2, Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, and Par-6) 
identified in a genetic screen conducted in C. elegans (Guo and Kemphues, 1995).  Par-1 
orthologs have subsequently been identified and studied in a number of organisms, 
including yeast, Drosophila, and mammals (Drewes et al., 1997; Elbert et al., 2005; La 
Carbona et al., 2004; Shulman et al., 2000; Trinczek et al., 2004) and have been 
implicated in regulating cell polarity and other cellular functions, such as mitogenic and 
Wnt signaling (Bohm et al., 1997; Cox et al., 2001; Muller et al., 2001; Ossipova et al., 
2005; Shulman et al., 2000; Sun et al., 2001; Tomancak et al., 2000).  In mammals there 
are four Par-1 family members: mPar-1a (C-TAK1/MARK3), mPar-1b (EMK/MARK2), 
mPar-1c (MARK1), and mPar-1d (MARKL1, MARK4).  Mammalian orthologs have 
been identified for all of the par genes except for Par-2.   
 In the C. elegans embryo, all of the Par proteins are enriched at or near the cell 
cortex, and most of the proteins adopt asymmetric localization patterns as cell 
polarization is established (Kemphues, 2000).  Par-3 and Par-6 become enriched in the 
anterior cortex during the one-cell stage, and Par-1 and Par-2 become enriched in the 
posterior cortex (Fig.1.1).  Par-4 (LKB1) and Par-5 remain symmetrically distributed and 
are both cortical and cytoplasmic.  Par proteins drive their own asymmetric localization 
by regulating motors or by establishing the conditions necessary in the cell cortex for 
asymmetric movements of cellular components (Goldstein and Macara, 2007).  The 
anterior Par proteins are required to prevent posterior Par proteins from localizing 
anteriorly, and vice versa (Kemphues, 2000).  Par-5 is required for the exclusion of both 
anterior and posterior  Par domains (Cuenca et al., 2003; Morton et al., 2002).  Par-1 
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membrane association at the posterior pole is dependent in part on Par-2 (Boyd et al., 
1996). 
 The C. elegans one-cell embryo becomes polarized by the contraction of the 
actomyosin cortex to one side of the cell (Fig. 1.1) (Munro, 2006).  The fertilizing sperm 
delivers two cues for the contraction: the sperm-derived centrosomes and a RhoGAP 
called CYK-4.  Rho affects myosin organization and activates myosin-based contraction 
and CYK-4 locally inactivates Rho, thus resulting in an inhibition of mysosin and 
breaking the actomyosin on one side of the cell allowing the cortex to contract away from 
the site of sperm entry (Goldstein and Macara, 2007).  The contraction of the cortex to 
one side moves the Par-3/Par-6/atypical protein kinase C (aPKC) complex toward the 
anterior; however, Par-6 and Par-2 associate with the moving cortex, suggesting that Par 
proteins may exchange rapidly on and off of the moving cortex rather than be moved 
(Munro et al., 2004).  Once the polarity is established at the anterior of the embryo and 
anterior Par proteins are in place, posterior Par proteins can then associate with the 
posterior cortex (Cuenca et al., 2003; Munro et al., 2004). 
 Once the two Par domains are established, the Par proteins function to maintain 
polarity on each end of the C. elegans embryo.  Two distinct domains are maintained in a 
positive feedback loop using phosphorylation as a means to maintain this polarity.  aPKC 
at the anterior of the embryo and Par-1 at the posterior inhibit specific proteins from 
associating locally.  In the anterior, aPKC phosphorylates Par-2 in order to prevent Par-2 
cortical association (Hao et al., 2006).  In the posterior, Par-2 prevents reverse cortical 
flow and blocks anterior Pars from associating by allowing Par-1 to accumulate at the 
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posterior cortex where it can cause disassembly of the anterior Par complexes (Cuenca et 
al., 2003). 
Epithelial polarization in C.elegans, Drosophila, and mammals  
 The formation and maintenance of epithelial sheets of cells with apical-basal 
polarity is essential throughout development and in adult organisms.  Junctions between 
the epithelial cells provide adhesion and control the permeability of the sheets to ions and 
molecules.  The physiological functions of epithelial cells depend on the asymmetric 
organization of cellular components such as the plasma membrane, organelles, and the 
cytoskeleton along the apical-basal axis (Rodriguez-Boulan and Nelson, 1989).  In the C. 
elegans embryo this organization and establishment of cell polarity has been shown to be 
dependent on the antagonistic relationship between Par-1 and the Par-3/Par-6/aPKC 
complex, and the same is likely true in epithelial cells of developed eukaryotic organisms.  
The fly ortholog of Par-3 functions in Drosophila epithelial cells to also drive apical-
basal polarization (Kuchinke et al., 1998); furthermore, in mammalian epithelia, Par-3 is 
localized to tight junctions at the apical/lateral boundary and functions in their assembly 
(Chen and Macara, 2005).  This discussion of polarity proteins extends to Par-1, as the 
phosphorylation of Par-1 by aPKC and PKD permits binding of Par-5 (14-3-3) and 
blocks membrane binding (Fig. 1.2) (Hurov et al., 2004; Suzuki et al., 2004; Watkins et 
al., 2008).  Conversely, Par-1 present at the lateral membrane can phosphorylate any Par-
3 molecule that is located in its vicinity (Fig. 1.2).  Phosphorylated Par-3 binds Par-5 (14-
3-3) and is released from the cell membrane, thus preventing the spread of Par-3 into the 
lateral membrane occupied by Par-1.  Therefore, the segregation of the Par proteins into 
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separate domains is maintained by exclusion which is driven by phosphorylation and Par-
5 (14-3-3) binding.  
 Par-1 and Par-4 also participate in epithelial polarization.  In mammalian cells 
Par-1 determines the organization of microtubules, which establish the position of the 
luminal surface (Cohen et al., 2004).  Hyperactive Par-1 converts columnar epithelial 
cells with vertical microtubules and an apical luminal surface into a hepatic type of 
epithelial cells with horizontal microtubules and lumens that form between adjacent cells.  
Par-1 is phosphorylated and activated by Par-4 (LKB1) (Fig. 1.3).  Mammalian Par-4 
(LKB1) is mutated in Peutz-Jeghers cancer syndrome (PJS).  This disease involves the 
epithelial cells of the gastrointestinal tract, pancreas, lungs, and reproductive organs 
(Baas et al., 2004b) even though Par-4 is expressed ubiquitously (Alessi et al., 2006).  
PJS patients frequently have mutations that truncate the kinase domain or result in loss of 
expression of LKB1 (Par-4).  In mammals, LKB1 (Par-4) functions as a master kinase 
that can phosphorylate and activate many downstream kinases, including Par-1, and it has 
been implicated in metabolic control, cell growth, and mitosis, in addition to cell 
polarization and asymmetric cell division (Alessi et al., 2006).  High Par-4/LKB1 activity 
can drive the polarization of isolated epithelial cells even in the absence of cell-cell 
contacts; however, the downstream kinase necessary for this is not Par-1, but AMPK, a 
kinase primarily thought of as a metabolic regulator that responds to energy deprivation 
(Lee et al., 2007; Mirouse et al., 2007).  It is interesting to note that a constitutively active 
AMPK can rescue many of the polarity defects that occur in Drosophila lkb1 null 
mutants through phosphorylation of the myosin light chain, and loss of either AMPK or 
Par-4/LKB1 results in a stress-dependent loss of epithelial cell polarity.  On the other 
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hand, activation of AMPK by energy deprivation can drive epithelial cell polarization.  
These results reveal a link between energy metabolism and the polarity/proliferation 
pathways.    
Par-1b and Par-1a knockout mice 
Another link between energy metabolism and the polarity/proliferation pathways 
is mammalian Par-1b/MARK2/EMK (mPar-1b).  Knockout studies of mice performed by 
our laboratory suggest that polarity kinase Par-1b/MARK2/EMK is required for 
regulating fertility, immune homeostasis, as well as glucose metabolism in vivo (Hurov et 
al., 2007).  Par-1b knockout mice are lean, insulin hypersensitive, resistant to high-fat 
diet-induced weight gain, and hypermetabolic.  Thus, mammalian Par-1b is a regulator of 
glucose metabolism and adiposity in the whole animal and may be a valuable drug target 
for the treatment of both type 2 diabetes and obesity. 
Similar to Par-1b/MARK2/EMK knockout mice, our lab has also shown that Par-
1a/MARK3/C-TAK1 null mice exhibit increased energy expenditure, reduced adiposity 
with unaltered glucose handling, and normal insulin sensitivity (Lennerz et al., 2010).  
Par-1a knockout mice are protected against high-fat diet-induced obesity and display 
attenuated weight gain, complete resistance to hepatic steatosis, and improved glucose 
handling with decreased insulin secretion (Lennerz et al., 2010).  Overnight starvation led 
to complete depletion of hepatic glycogen supply, associated hypoketotic hypoglycemia, 
increased hepatocellular autophagy, and increased glycogen synthase levels in Par-1a null 
but not in control or Par-1b null mice.  When Par-1a null mice were intercrossed with 
Par-1b null mice it was noticed that at least one of the four alleles is necessary for 
embryonic survival.  Interestingly, the loss of one Par-1b allele in Par-1a null mice 
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conveyed milder phenotypes than the loss of one Par-1a allele in Par-1b null mice. Thus, 
although Par-1a and Par-1b can compensate for one another during embryogenesis, their 
individual and specific disruption gives rise to unique metabolic phenotypes in adult mice. 
Par-1b protein domains and known posttranslational modifications 
 Par-1 is a serine/threonine protein kinase comprised of an amino-terminal kinase 
domain, followed by a ubiquitin-associated domain (UBA), a nonconserved spacer region, 
and ending with a conserved region of about 100 amino acids that terminates with the 
sequence glutamate-leucine-lysine/asparagine-leucine (Fig. 1.3) (Marx et al., 2006).  This 
region has been referred to as the “ELKL” domain and murine EMK derived its name 
from ELKL motif kinase.  Par-1 is activated by phosphorylation within its activation loop 
on Threonine (T)208 (Fig. 1.3).  Activation loop phosphorylation can be catalyzed by 
Par-1b itself, by the tumor suppressor LKB1 (Par-4) (Lizcano et al., 2004) or by 
MARKK (Timm et al., 2003).  The presence of a UBA domain adjacent to the catalytic 
domain suggests potential interactions between Par-1b and proteins involved in the 
ubiquitin proteasome pathway, DNA repair, and/or cell signaling (Brajenovic et al., 2004; 
Hofmann and Bucher, 1996; Mueller and Feigon, 2002).  However, one study reported 
that the UBA domain of Par-1b may not bind ubiquitin, but rather serve as an inhibitory 
domain (Murphy et al., 2007; Panneerselvam et al., 2006).   
Downstream of the UBA domain is a region that is not highly conserved among 
Par-1 orthologs.  We identified two phosphorylation sites (Serine (S)400 and T595) 
within this region that are conserved among many orthologs (Fig. 1.3) (Hurov et al., 
2004; Watkins et al., 2008).  Furthermore, our work has demonstrated that these sites are 
regulated by two different arms of the Protein Kinase C (PKC) pathway.  T595 is 
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phosphorylated by aPKC (Hurov et al., 2004) whereas my work has shown that S400 is 
phosphorylated by PKD through activation of novel PKCs (nPKCs) (Watkins et al., 
2008).  The nPKC pathway is activated by the PKC activator phorbol-12-myristate-13-
acetate (PMA) in vivo.  Moreover, both phosphorylation sites contribute to interactions 
between Par-1b and 14-3-3 proteins (Benton and St Johnston, 2003; Goransson et al., 
2006; Suzuki et al., 2004).  14-3-3 proteins, themselves members of the Par family (Par-
5), interact with phospho-Ser or phospho-Thr motifs and modulate diverse cellular 
processes (Fu et al., 2000; Mackintosh, 2004; Muslin and Xing, 2000).  In addition to 
directly binding to 14-3-3 proteins, Par-1 proteins also phosphorylate other proteins to 
regulate their interactions with 14-3-3 proteins: the kinase suppressor of Raf-1 (KSR1), 
which functions as a docking platform for components of the Ras-MAPK pathway 
(Muller et al., 2001); protein-tyrosine phosphatase H1, which regulates cell-cycle 
progression and attenuates T-cell-receptor signaling (Zhang et al., 1997); plakophilin2, a 
desmosomal protein (Muller et al., 2003), and PAR-3 (Benton and St Johnston, 2003). 
RNF41 protein domains 
 In an effort to identify Par-1 interacting proteins, human Par protein complexes 
were mapped out using tandem affinity purification (TAP) and the resulting network of 
proteins identified novel interactors of human Par-1 (hPar-1d/MARK4) such as the 
ubiquitin ligase NRDP1 (neuregulin receptor degradation protein-1)/RNF41 (Brajenovic 
et al., 2004).  RNF41 is composed of an N-terminal RING domain, two zinc-finger 
domains collectively called the B-Box, a coiled-coil segment, and a C-terminal receptor 
binding domain (Abdullah et al., 2001; Bouyain and Leahy, 2007) (Fig. 1.4).  Out of the 
six par genes in C. elegans, orthologs of every gene except Par-2 have been identified in 
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mammals.  Par-2 is a RING finger-containing protein and has homology with RNF41 in 
both the RING domain and a portion of the C-terminus leaving open the interesting 
possibility that RNF41 is an ortholog of Par-2. 
While the N-terminal motif of RNF41 is characteristic of a family of E3 ubiquitin 
ligases, called TRIM/RBCC (Tripartite Motif/Ring B-Box Coiled-coil) proteins, it is the 
diversity of the C-terminal ends of these proteins that is thought to be involved in 
selectively recognizing target proteins.  Of interest is the C-terminal end of RNF41 as it 
has no homology with other proteins of known structure (Diamonti et al., 2002; Qiu and 
Goldberg, 2002) and binds specifically to its substrates, such as ErbB3, BRUCE, 
PARKIN, and others via specific residues (Bouyain and Leahy, 2007).  Unlike most other 
membrane receptors, ErbB3 does not undergo degradation by lysosomes (Levkowitz et 
al., 1999; Qiu and Goldberg, 2002; Waterman et al., 1998), but rather is degraded by the 
proteasome and this process is catalyzed by the ubiquitin ligase RNF41 (Qiu and 
Goldberg, 2002).  Mutation of cysteine, histidine, and aspartate residues in the RING 
domain of RNF41 inhibits its E3 ligase activity and thus degradation of ErbB3. 
Additionally, the RING and B-box motifs at the N-terminus of RNF41 are not required 
for binding to ErbB3 (Qiu and Goldberg, 2002) yet are required for ERBB3 degradation.  
Interestingly, expression of an RNF41 mutant containing only the coiled-coil and C-
terminal domains caused ErbB3 to accumulate (Diamonti et al., 2002; Qiu and Goldberg, 
2002).  Therefore, RNF41 binds ErbB3 receptors through its C-terminal end; however, it 
is its N-terminal RING domain which provides its function as an E3 ubiquitin ligase and 
signal for ErbB3 degradation. 
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RNF41 regulation 
RNF41 is extremely unstable when transfected or transduced in a variety of cell 
lines, often requiring treatment of cells with the proteasome inhibitor MG132 in order to 
detect endogenous RNF41 protein by Western blot.  Point mutations in the RING finger 
domain that disrupt zinc ion coordination and thus coupling to E2 ubiquitin conjugating 
enzymes stabilize RNF41 protein, suggesting that the lability of RNF41 protein may be 
due in a large part to autoubiquitination (Carraway).    
In order to elucidate mechanisms of RNF41 regulation, interacting proteins were 
identified by affinity chromatography/tandem mass spectrometry.  Among the proteins 
identified was USP8 (Wu et al., 2004), a deubiquitinating enzyme.  After characterization 
of this protein-protein interaction, it was found that the carboxy terminal domain of 
RNF41 binds to the rhodanese domain of USP8, and that USP8 very efficiently 
deubiquitinates and stabilizes RNF41 (Wu et al., 2004).  Moreover, it was observed that 
treatment of cells with the growth factor Neuregulin-1! (NRG1!) stabilizes RNF41 
through USP8 (Cao et al., 2007).  NRG1! stimulation of the ErbB2/ErbB3 heterodimer 
activates phosphatidylinositol 3-kinase (PI3K), in turn activating AKT, which 
phosphorylates murine USP8 on threonine 907.  USP8 phosphorylation leads to its 
activation and stabilization, thus stabilizing RNF41.  The resulting feedback loop 
provides a mechanism for ligand-induced degradation of ErbB3, and furthermore it has 
been demonstrated that RNF41 or USP8 knockdown in MCF7 breast tumor cells 
suppresses NRG1!-stimulated ErbB3 ubiquitination and degradation(Cao et al., 2007). 
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ErbB receptor tyrosine kinase signaling and breast cancer 
The ErbB family of receptor tyrosine kinases regulates various cellular processes 
such as proliferation, differentiation, cell survival, migration, and invasion (Yarden and 
Sliwkowski, 2001; Yen et al., 2006).  Members of this family include the epidermal 
growth factor receptor (EGFR/ErbB1), HER2/c-neu (ErbB2), HER3 (ErbB3), and HER4 
(ErbB4).  Furthermore, aberrant expression of these receptors is commonly found in 
human cancers and is associated with aggressive disease (Hynes and Stern, 1994; 
Salomon et al., 1995; Yarden and Sliwkowski, 2001; Yen et al., 2006).   
The ErbB signaling network is complex due to the existence of multiple ligands, 
each with specificity for distinct members of the ErbB family.  The ErbB receptors signal 
through the formation of ligand-induced homodimers and heterodimers between the 
different family members (Alroy and Yarden, 1997; Carraway and Cantley, 1994; Riese 
and Stern, 1998; Yen et al., 2006), which then activate diverse signaling pathways (Alroy 
and Yarden, 1997; Carraway and Cantley, 1994).  Binding of peptides of the EGF-related 
growth factor family to the extracellular domain of ErbB receptors results in the 
formation of these homo- and heterodimers.  Ligand binding induces the intrinsic 
receptor kinase activity, leading to stimulation of the intracellular signaling cascades 
(Yarden and Sliwkowski, 2001).  Moreover, the ErbB3 receptor has impaired kinase 
activity (Guy et al., 1994), whereas the ErbB2 receptor has no known ligand.  Thus, both 
receptors must form receptor heterodimers in order to signal.  Neuregulin-1 (NRG1) 
growth factor binds to its ErbB3 receptor preferentially resulting in ErbB2/ErbB3 
heterodimer formation (Citri et al., 2003; Yen et al., 2006) and initiating extracellular-
related kinase/ mitogen-activated protein kinase (ERK/MAPK) and PI3K pathway 
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activation (Alimandi et al., 1995; Ben-Levy et al., 1994; Holbro et al., 2003; Peles et al., 
1992; Yen et al., 2006).  
It has widely been demonstrated that ErbB receptor tyrosine kinases, in particular 
ErbB1 and ErbB2, have roles in human cancer development, thus making them attractive 
targets for cancer therapies (Hynes and Stern, 1994; Mendelsohn and Baselga, 2000; 
Salomon et al., 1995; Shawver et al., 2002).  ErbB2 overexpression, which is generally 
due to gene amplification, occurs in 25-30% of breast cancer and correlates with shorter 
time to relapse and lower overall survival (Slamon et al., 1987).  Overexpressed ErbB2 is 
constitutively phosphorylated in breast cancer cell lines and in human tumors (Alimandi 
et al., 1995).  It has been observed that targeting overexpressed active ErbB2 results in 
efficient inhibition of breast cancer cell proliferation (Lane et al., 2000; Munster et al., 
2002; Neve et al., 2000; Yakes et al., 2002).   
Interestingly, expression of ErbB3 is seen in many tumors that express ErbB2, 
including breast (Naidu et al., 1998), bladder (Chow et al., 2001), and others.  
Furthermore, in many ErbB2-overexpressing breast tumors, ErbB3 has elevated levels of 
phosphotyrosine (Alimandi et al., 1995).  Several groups have shown that inactivation of 
ErbB2 leads to a decrease in ErbB3 tyrosine phosphorylation (Basso et al., 2002; Lane et 
al., 2000; Motoyama et al., 2002; Neve et al., 2000).  ErbB3, which contains six docking 
sites for the p85 adaptor subunit of PI3K, efficiently couples to this pathway (Fedi et al., 
1994; Prigent and Gullick, 1994).  Interestingly, it has been observed that a major 
consequence of targeting overexpressed ErbB2 is decreased PI3K (Basso et al., 2002; 
Lane et al., 2000; Neve et al., 2000), suggesting a role for ErbB3 in stimulation of this 
pathway downstream of active ErbB2. 
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Finally, it has been shown in breast cancer cells that constitutive tyrosine 
phosphorylation on ErbB3 depends on the activity of overexpressed ErbB2 (Holbro et al., 
2003).  Activity of the PI3K pathway depends fully on the recruitment of p85 to phospho-
ErbB3.  Importantly, inactivation of ErbB3 blocks proliferation of breast cancer cells as 
efficiently as inhibiting ErbB2 signaling (Holbro et al., 2003).  Expression of 
constitutively active PI3K rescues the proliferative block induced due to the loss of 
ErbB2 or ErbB3 signaling.  Taken together, these results suggest that the ErbB2/ErbB3 
dimer functions as an oncogenic unit to drive tumor cell proliferation.   
RNF41 involvement in ErbB3 overexpression in mammary tumors 
 Several mechanisms account for ErbB3 overexpression in tumors.  Amplification 
of the erbB3 gene has been reported, but PCR and FISH results suggest that this is not as 
prevalent as erbB2 amplification (Sassen et al., 2008; Zaczek et al., 2008) and does not 
account for the frequency of elevated ErbB3 protein observed in tumors.  Although 
ErbB3 overexpression is a common occurrence in breast tumors, and ErbB3 levels may 
be regulated post-transcriptionally in mouse mammary tumors (Miller et al., 2008; Siegel 
and Muller, 1996; Yen et al., 2006), the question remains whether the RNF41 pathway is 
deregulated in tumors, and if so, whether deregulation contributes to tumor initiation or 
progression.  It has previously been observed that RNF41 protein is lost in ErbB2-driven 
mammary tumors from transgenic mice and this loss cannot be attributed to a reduction in 
message levels (Carraway).  Furthermore, RNF41 protein is suppressed in 57% of tumors 
when comparing patient-matched normal and tumor breast tissues, and there is a strong 
inverse correlation between RNF41 and ErbB3 protein levels in patient tumors (Yen et al., 
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2006).  All of this data is suggestive that loss of RNF41 contributes to ErbB3 protein 
overexpression in both human and mouse tissue samples. 
 Surprisingly, crossing MMTV-RNF41 mice into an ErbB2 overexpression model 
had little effect on tumor latency or burden, or on ErbB3 protein overexpression (Ingalla 
et al.), even though RNF41 transcript levels were 10-fold higher in bigenic animals than 
in MMTV-ErbB2 mice.  Immunoblotting studies revealed that the ErbB2-induced mouse 
mammary tumors lacked both endogenous and overexpressed RNF41 protein.  Consistent 
with this, cultured ErbB2-positive breast tumor cells are resistant to the expression of 
exogenous RNF41, while non-transformed cells efficiently support RNF41 expression 
(Ingalla et al.).  These observations indicate that like ErbB2 and ErbB3, RNF41 levels are 
deregulated in tumor cells by posttranscriptional mechanisms.   
3D models of glandular epithelium 
Under 3D culture conditions, normal epithelial cells proliferate and organize into 
spheroids (acini), which are known to have a centrally-localized, hollow lumen with 
polarized cells surrounding this lumen (Fig. 1.5) (Debnath et al., 2003; Petersen et al., 
1992; Streuli and Bissell, 1990).  These 3D culture systems address some of the 
limitations of monolayer (2D cell culture) cell cultures, mouse models, or human tissues.  
3D cell cultures are easily manipulated experimentally and can be analyzed 
biochemically and using microscopy.  Furthermore, 3D cell cultures contain essential 
structural features of glandular epithelium in vivo.  Early studies revealed that human 
breast tumor cell lines did not form acini when grown in 3D culture; rather, they develop 
into nonpolarized clusters (Petersen et al., 1992).  These experiments illustrated the 
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difference in behavior between normal and tumor cells in 3D culture, even though subtle 
difference were noted when the same cells were grown as monolayers. 
The cells comprising glandular epithelial tissues exhibit a characteristic polarity, 
such that their apical poles point towards the central lumen.  This polarity is often 
disrupted in carcinomas, which is generally considered a poor prognostic sign.  MDCK 
cyst models have demonstrated that epithelial cells possess hard-wired mechanisms for 
generating polarity within the context of a 3D tissue structure.  Furthermore, it has been 
demonstrated that the ECM plays a fundamental role in directing these mechanisms 
(O'Brien et al., 2002).   
Epithelial cell polarity and cancer 
 The majority of human cancers are derived from epithelial tissues, and display 
loss of cell polarity and often, as a consequence, tissue disorganization.  Although the 
tumor suppressive function of polarity complexes is well established in Drosophila, it 
remains unclear whether a loss of cell polarity is a consequence or cause of human 
cancers.  However, it is now suggested that epithelial cell polarity may exert a tumor 
suppressive function in mammals through its participation in the establishment and 
maintenance of the 3D organization of epithelial tissues as a whole.  This is supported by 
the findings that polarity proteins are cellular targets of oncogenes and tumor suppressors 
(Royer and Lu). 
 Apical-basal polarity has two fundamental roles in epithelial cells that are linked 
to tumor suppression: the regulation of asymmetric cell division and the maintenance of 
the apical junctional complex (AJC).  In epithelial stem cells, polarity proteins control 
asymmetric cell divisions by regulating the localization of cell fate determinants and the 
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correct orientation of mitotic spindles.  Thus, asymmetric cell division has a role in the 
control of progenitor or stem cell numbers and differentiation.  This is of interest in the 
context of the cancer stem cell theory, as shifting from asymmetric division of epithelial 
stem cells or cancer-initiating cells towards symmetric divisions would result in 
dedifferentiation and an increase in cancer-initiating cells.  Thus, a defect in asymmetric 
division could contribute to the development of tumors. 
 In addition to their role in the prevention of tumor initiation, core epithelial cell 
polarity mechanisms may also behave as a barrier to tumor metastasis and malignancy 
through their close connection to the AJC.  The AJC contains both tight and adherens 
junction complexes, and its structure is dependent on the integrity of the apical and 
basolateral polarity complexes.  The loss of one of the key components of adherens 
junctions, E-cadherin, often occurs in later stages of tumorigenesis and is thought to 
contribute to epithelial mesenchymal transition (EMT), which represents a crucial step in 
metastasis.  The importance of the AJC in supporting cancer malignancy is supported by 
cancer genome sequencing data which show that a large number of AJC components are 
frequently mutatated in human cancers.   
 Evidence indicates that loss of cell polarity is not merely a byproduct of abnormal 
cell proliferation, but rather is caused by the direct disruption of cell-polarity mechanisms 
by oncogenic signaling (Fig. 1.6).  One example, E6 oncogenes, found in human 
papilloma virus (HPV), target cell polarity proteins Dislarged (Dlg) and Scribble (Scrib) 
for proteolytic degradation (Fig. 1.6) (Lee and Vasioukhin, 2008).  The ability to degrade 
these cell polarity proteins correlates with the malignant potential of E6 oncogenes.  In 
addition to viral oncogenes, malignant transformations can be induced by the abnormal 
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activation of various growth factor signaling pathways such as transforming growth 
factor ! (TGF!), resulting in the stimulation of cell proliferation and disruption of apical-
basal polarity, cell-cell adhesion, and sometimes a complete epithelial-mesenchymal 
transition (EMT).  AJC-localized Par6 directly interacts with TGF! receptors and is a 
substrate for TGF!RII-mediated phosphorylation (Ozdamar et al., 2005).  Activation of 
TGF! signaling results in phosphorylation of Par6, which promotes its interaction with 
the E3 ubiquitin ligase Smurf1.  Localized to the AJCs, Smurf1 targets junctional RhoA 
for degradation.  RhoA is crucial for the maintenance of the actin cytoskeleton and 
stabilization of AJCs; thus, activation of TGF! signaling results in the destabilization and 
loss of AJCs and the initiation of EMT (Fig. 1.6). 
 Abnormal activation of the receptor tyrosine kinase ErbB2 is implicated in human 
breast, ovarian, gastric, esophageal, and endometrial cancers (Hynes and Lane, 2005; 
Linggi and Carpenter, 2006; Moasser, 2007).  Whereas ErbB2 stimulates cell 
proliferation by activating the PI3K pathway, it can also directly disrupt cell polarity and 
provide protection from apoptosis through its interaction with the Par6-aPKC protein 
complex (Aranda et al., 2006).  Activation of ErbB2 results in the dissociation of Par3 
from the Par6-aPKC complex (Fig 1.6).  Inhibition of this dissociation restores correct 
cell polarity and abrogates the anti-apoptotic effects of ErbB2.  These findings indicate 
that growth-factor receptors can use independent mechanisms to regulate proliferation 
and polarity, and that it is possible to activate cell proliferation without inducing cell-
polarity defects. 
 In addition to oncogenes and proto-oncogenes, tumor suppressors are also 
involved in the regulation of apical-basal cell polarity.  Mutations in the von Hippel-
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Lindau (VHL) tumor suppressor are responsible for von Hippel-Lindau disease, which is 
characterized by the development of hemangioblastoma, clear-cell renal carcinoma and 
pheochromocytomas (Kaelin, 2005; Kaelin, 2007).  VHL polyubiquitinates and targets 
the transcription factor hypoxia-inducible factor 1 (HIF1) for degradation.  VHL directly 
impacts cell polarity pathways by ubiquitin-mediated degradation of activated aPKC (Fig 
1.6) (Okuda et al., 2001).  Furthermore, interaction between VHL and the Par3-Par6-
aPKC complex is involved in VHL-mediated regulation of polarized microtubule growth 
and formation of primary cilia (Schermer et al., 2006).  This function makes VHL an 
important regulator of cell polarity because polarized growth of microtubules is crucial 
for cell polarization.   
 Phosphatase and tensin homolog (PTEN) is another tumor suppressor protein that 
is implicated in the regulation of cell polarity.  PTEN negatively regulates the PI3K 
pathway (Rossi and Weissman, 2006).  Spatial membrane segregation of PI3K pathway 
regulators is important for apical-basal cell polarity (Fig.1.6)(Martin-Belmonte et al., 
2007).  Thus, PTEN is necessary for the establishment and maintenance of apical-basal 
cell polarity. 
 Finally, in addition to PTEN, LKB1 is another dual-function protein that is 
directly involved in both cell polarity and tumor suppression.  As previously described, 
mutations in LKB1 are responsible for Peutz-Jeghers syndrome.  LKB1 is a homologue 
of the Drosophila and C. elegans cell polarity protein Par4 and its function is also 
important for establishing polarity in mammalian cells (Baas et al., 2004a).  LKB1 
phosphorylates and activates several other serine/threonine protein kinases including 
AMP-activated protein kinase (AMPK) and Par1 (Fig 1.6) (Lizcano et al., 2004).  AMPK 
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controls cell polarity by regulating the acto-myosin cytoskeleton via phosphorylation of 
the non-muscle myosin regulatory light chain (MRLC) protein (Lee 2007).  The 
discovery of AMPK as a regulator of cell polarity indicates that LKB1-mediated control 
of cell growth and polarity are connected to each other. 
Summary 
 The major goal of my thesis work was to investigate functional interactions 
between the Par-1b protein kinase and the RNF41 E3 ubiquitin ligase.  Atypical Protein 
Kinase C (aPKC) phosphorylates Par-1b on a conserved threonine residue (T595) and I 
participated in studies demonstrating that novel Protein Kinase C (nPKC) activates 
Protein Kinase D (PKD) to directly phosphorylate Par-1b on serine 400 (S400), a residue 
that is conserved in all four mammalian Par-1 kinases as well as the fly ortholog.  
Phosphorylation of Par-1b on T595 and S400 causes Par-1b to relocate from membranes 
to the cytosol and to bind 14-3-3 proteins.  In 2004, Brajenovic, et al. reported the results 
of a study that used tandem affinity purification (TAP) to isolate human Par-1d along 
with associated proteins.  Nrdp1/RNF41, a ring finger E3 ligase was identified in their 
screen along with 14-3-3 and aPKC.  I found that Par-1b also binds to RNF41 and 
identified RNF41 as a novel cell polarity determinant.  My work demonstrated that 
phosphorylation of RNF41 on S254 by Par-1b is necessary for establishing epithelial cell 
polarity. 
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           Fig.1.1 Mechanisms that localize Par proteins.   
            Sperm-contributed nucleus and centrosome-nucleated microtubules are on the 
right side of the C. elegans embryo.  Arrows indicate spread of the cortex to which 
Par-2 associates as actomyosin contraction occurs.  [Adapted from (Goldstein and 
Macara, 2007)] 
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Fig. 1.2 Mechanisms of establishing epithelial cell polarity. 
Par-1 that has diffused onto the apical domain is phosphorylated by 
aPKC, thus inhibiting the Par-1 kinase activity and inducing binding of 
Par-5/14-3-3, which in turn triggers release of Par-1 into the cytoplasm. 
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Fig. 1.3  Diagram of the domains of Par-1b protein and upstream 
signaling. [(*) indicates autophosphorylation]  LKB1 phosphorylates 
Par-1b to activate Par-1b signaling.  Additionally, Par-1b is 
phosphorylated by two arms of the PKC pathway on two sites (S400 
and T595).  
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Fig. 1.4  Diagram of the domains of RNF41 protein. 
Indicated are amino acids known to be of importance for substrate binding 
and/or E3 ligase activity.  Serine 254, a site phosphorylated by Par-1b, is 
indicated in bold.   
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 Fig. 1.5 Events in MCF10A morphogenesis in 3D culture. 
During the early stages of 3D culture, apical-basal polarization becomes evident 
within cell clusters before evidence of lumen formation. At day 5-8 in culture, 
two distinct populations of cells become evident within each acinus: an outer 
layer of cells in direct contact with the matrix (marked by laminin 5 staining on 
day 4) and inner cells lacking matrix contact. Throughout morphogenesis, this 
outer cell layer remains polarized with respect to the acinus center (indicated by 
the apical orientation of the golgi protein, GM130).  Starting at day 8,the 
centrally located cells undergo cell death, which involves apoptosis, 
characterized by the expression of active caspase 3.  This cell death contributes 
to the formation of a hollow lumen. The acinus remains hollow thereafter. 
[Adapted from (Debnath and Brugge, 2005)] 
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Fig. 1.6 Oncogenic and tumor suppressor signaling pathways target cell-
polarity mechanisms.  (A) Viral E6 oncogene from human HPV targets Dlg and 
Scrib proteins for ubiquitin-mediated degradation.  (B) Activation of TGF! signaling 
results in phosphorylation of Par6, and targeting of the E3 ubiquitin ligase Smurf1 to 
the AJCs, where Smurf1 destroys RhoA, disrupts the integrity of AJCs and causes 
EMT. (C) Activation of ErbB2 signaling results in disruption of the apical Par6-
Par3-aPKC polarity complex by promoting dissociation between Par3 and Par6-
aPKC. (D) TheVHL tumor suppressor ubiquitinates active aPKC and targets it for 
proteasome-mediated degradation.  In addition, interaction between VHL and the 
Par3-Par6-aPKC polarity complex is necessary for correct orientation of the 
microtubules and for primary cilia formation. (E) During polarization of epithelial 
cells PTEN is targeted to the future apical membrane domain (F) The tumor 
suppressor LKB1 controls cell polarity, growth and proliferation by regulating the 
activities of AMPK and Par1 protein kinases. [Adapted from (Lee and Vasioukhin, 
2008)] 
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Abstract 
The Par-1 protein kinases are conserved from yeast to humans where they 
function as key polarity determinants. The mammalian Par-1 family is comprised of four 
members (Par-1a, b, c and d). Previously, we demonstrated that atypical protein kinase C 
(aPKC) phosphorylates the Par-1 kinases on a conserved threonine residue (T595) to 
regulate localization and kinase activity.  Here we demonstrate that Par-1b is also 
regulated by another arm of the PKC pathway, one that involves novel PKCs (nPKC) and 
Protein Kinase D (PKD).  Treatment of cells with the PKC activator phorbol-12-
myristate-13-acetate (PMA) potently stimulated phosphorylation of Par-1b on serine 400 
(S400), a residue that is conserved in all four mammalian Par-1 kinases as well as the fly 
ortholog.  We demonstrate that PMA stimulates nPKC to activate PKD, which in turn 
directly phosphorylates Par-1b on S400 to positively regulate 14-3-3 binding and to 
negatively regulate membrane association.  Thus, two arms of the PKC pathway regulate 
interactions between Par-1b and 14-3-3 proteins: one involving aPKC and the other 
nPKC/PKD. 
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Introduction 
 Establishing and maintaining cellular polarity is critical for the homeostasis of 
unicellular and multicellular organisms alike.  The PAR (partitioning-defective) genes 
(PAR 1-6) were identified in Caenorhabditis elegans as essential determinants of 
asymmetric cell division and polarized cell growth(Kemphues, 2000; Kemphues et al., 
1988). Par-1 is a serine/threonine protein kinase and Par-1 homologues have been 
identified and studied in a number of organisms, including yeast, fruitflies, frogs and 
mammals (Goldstein and Macara, 2007; Tassan et al., 1994). These studies have revealed 
disparate roles for Par-1 not only as a regulator of cell polarity but also as a component of 
mitogenic and Wnt signaling (Hurov and Piwnica-Worms, 2007; Tassan et al., 1994). In 
mammals there are four Par-1 family members named Par-1a (C-TAK1/MARK3), Par-1b 
(EMK/MARK2), Par-1c (MARK1), and Par-1d (MARKL1, MARK4).  
Several Par-1 substrates have been identified, including Par-3 (Benton and St 
Johnston, 2003; Hurd et al., 2003).  An antagonistic relationship between Par-1 and the 
Par-3/Par-6/aPKC complex has been revealed. In C. elegans embryos Par-1 is located at 
the posterior cortex whereas the Par3/Par6/aPKC complex is located at the anterior cortex.  
In epithelial cells, the Par3/Par6/aPKC complex is found at tight junctions whereas Par1 
is located laterally beneath tight junctions. Par-1 phosphorylates Par-3 to exclude it from 
lateral membranes of epithelial cells (Benton and St Johnston, 2003; Hurd et al., 2003), 
whereas aPKC in complex with Par-3/Par-6 phosphorylates Par-1 to dislodge it from 
plasma membranes(Hurov et al., 2004a; Suzuki et al., 2004). Thus, the establishment 
and/or maintenance of cell polarity likely require that Par-1 be physically sequestered 
from the Par-3/Par-6/aPKC complex and phosphorylation of Par-1 by aPKC may enforce 
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the mutual exclusion of Par-1 and Par-3/Par-6/aPKC.  Negative regulation of Par-1b by 
the Par-3/Par-6/aPKC complex is also observed in hippocampal neurons (Chen et al., 
2006). Here, we identify another protein kinase pathway that regulates Par-1 localization. 
We demonstrate that treatment of cells with PMA activates nPKCs to activate PKD and 
that PKD directly phosphorylates Par-1b on S400. Phosphorylation of S400, like 
phosphorylation of T595, regulates Par-1b/14-3-3 interactions and the ability of Par-1b to 
associate with cellular membranes. 
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Results 
Using a combination of site-directed mutagenesis and tryptic phosphopeptide 
mapping, we identified serine 400 (S400) as a potential site of Par-1b phosphorylation in 
vivo (data not shown). To verify that Par-1b is indeed phosphorylated on S400 in vivo, a 
phosphospecific antibody was generated and used in Western blotting experiments (Fig. 
2.1A, upper panel).  Whereas the pS400 antibody recognized Par-1b (lane 2), mutation of 
S400 eliminated its recognition by the antibody (lane 4). Thus, the antibody is specific for 
Par-1b when it is phosphorylated on S400 and ectopically expressed Par-1b is 
phosphorylated on S400 in cultured cells.  In addition, phosphorylation of S400 did not 
require the kinase activity of Par-1b as a kinase-inactive mutant of Par-1b was also 
phosphorylated on S400 in vivo (lane 3).  The status of endogenous Par-1b 
phosphorylation was interrogated in several mammalian cell lines using the pS400 
antibody (Fig. 2.1B). Two electrophoretic forms of Par-1b that arise by alternative 
splicing (Hurov  et al., 2001; Hurov et al., 2004b) were detected in each cell line and both 
splice variants reacted with the phosphospecific antibody. Thus, endogenous Par-1b is 
phosphorylated on S400 in vivo.  
Members of the Par-1 family share a conserved amino-terminal kinase domain, 
followed by a UBA domain, a divergent region of unknown function and a conserved C-
terminal region of approximately 100 amino acids (Fig. 2.S1). Serine 400 resides within 
the divergent region and is conserved in all four human Par-1 kinases as well as the fly, 
but not worm ortholog (Fig. 2.1C).  Par-1a also reacted with the pS400 antibody 
demonstrating that Par-1a is also phosphorylated on S410 (S400 equivalent) in vivo (Fig. 
2.S1B). The pS400-specific antibody did not recognize Par-1c and Par-1d and this is 
 -42- 
likely due to the fact that the phosphopeptide used to generate the pS400-specific 
antibody varies significantly in sequence from residues surrounding the equivalent 
phosphorylation sites in Par-1c and Par-1d (Fig. 2.1C).   
Interestingly, sequences inclusive of and surrounding S400 resemble a mode I 14-
3-3 binding motif (Muslin et al., 1996; Yaffe et al., 1997) and Par-1b binds 14-3-3 
proteins (Benton and St Johnston, 2003; Goransson et al., 2006; Meek et al., 2004a; 
Suzuki et al., 2004). We tested whether S400 regulated interactions between Par-1b and 
14-3-3 proteins in two ways.  First, co-precipitation of 14-3-3 proteins with wild type and 
mutant forms of Par-1b were examined and secondly Far Western analysis with purified 
14-3-3 proteins was employed.  As seen in Fig. 2.2A, co-precipitation of 14-3-3 proteins 
with wild-type (WT, lane 2) and kinase-inactive Par-1b (lane 3) was observed.  
Substitution of S400 with alanine diminished, but did not eliminate, 14-3-3 binding to 
Par-1b (lane 4).  Far Western analysis confirmed that mutation of S400 reduced 
interactions between Par-1b and 14-3-3 proteins (Fig. 2.2B, lane 5).  A truncation mutant 
of Par-1b consisting of amino acids 1- 470 but lacking S400 failed to bind 14-3-3 
proteins (lane 6) indicating that phosphorylation of S400 regulated interactions between 
14-3-3 proteins and the amino terminus of Par-1b.  Additional 14-3-3 binding site(s) must 
reside within the C-terminus of Par-1b given that mutation of S400 diminished but did 
not eliminate interactions between 14-3-3 proteins with full length Par-1b (Fig. 2.2A). A 
previous study reported that 14-3-3 binding is facilitated by T595 phosphorylation 
(Suzuki et al., 2004). We monitored WT and mutant forms of Par-1b for their ability to 
bind to 14-3-3 proteins and to be phosphorylated on S400 and T595 in vivo (Fig. 2.2C, 
2.S1C).  We observed that substitution of T595 with alanine reduced interactions between 
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Par-1b and 14-3-3 proteins as did substitution of S400 with alanine. Simultaneous 
mutation of both phosphorylation sites severely compromised binding of 14-3-3 proteins 
to Par-1b. 
In our search to identify signaling pathways that regulate Par-1b in vivo, we 
observed that treatment of cells with the protein kinase C (PKC) activator PMA potently 
stimulated phosphorylation of endogenous (Fig. 2.2D) and ectopically-produced (Fig. 
2.2E, lane 2) Par-1b on S400 in vivo. In addition, Far Western analysis demonstrated that 
PMA-treatment enhanced the binding of 14-3-3 proteins to Par-1b (Fig. 2.2E, lane 4).  
Although PMA enhanced the binding of 14-3-3 proteins to Par-1b, its relative binding to 
WT and mutant forms of Par-1b was not significantly altered in PMA-treated cells (Fig. 
2.S1D).  Enhanced Par-1b phosphorylation on S400 by PMA implicated members of the 
PKC family as upstream regulators of Par-1b.  In particular, both the conventional PKC 
(cPKCs) and novel PKCs (nPKC) are activated by DAG or phorbol esters (Newton, 
1997). Sequences surrounding and inclusive of S400 (KVQRSVpSA) do not form a 
consensus PKC phosphorylation site but rather more closely resemble that of a PKD 
consensus site (Fig. 2.1C) (Nishikawa et al., 1997). A major pathway for the activation of 
PKD is translocation to membrane compartments via binding to DAG or phorbol esters 
followed by phosphorylation of activation loop residues by novel PKCs (!, ", #, $), 
which are directly activated by PMA (Rozengurt et al., 2005).  As seen in Fig. 2.S1E, 
PMA treatment resulted in activation loop phosphorylation of both PKD1 (lane 2) and 
PKD2 (lane 4) indicative of PKD activation. 
Several experiments were performed to determine if Par-1b is directly regulated 
by PKD.  First, the phosphorylation status of Par-1b was monitored after co-production 
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with wild type and mutant forms of PKD1 and PKC! (Fig. 2.3A).  Enhanced S400-
phosphorylation was observed when Par-1b was co-produced with either WT PKD1 (lane 
3), WT PKC! (lane 4) or both PKD1 and PKC! (lane 5).  In addition, the stimulatory 
effects of PKD1 and PKC! on Par-1b S400-phosphorylation were blocked by kinase-
inactive PKC! (lane 6) and kinase-inactive PKD1 (lane 7), respectively. Importantly, 
kinase–inactive PKC! was unable to block the stimulatory effects of constitutively active 
PKD1 on Par-1b S400 phosphorylation (lane 8).  These findings suggest that PKC! 
functions upstream of PKD to regulate phosphorylation of Par-1b on S400.  Next, kinase 
assays were performed in vitro to determine if Par-1b was a direct substrate of either 
PKC! or PKD1 (Fig. 2.3B). PKD1 phosphorylated a kinase-inactive mutant of Par-1b on 
S400 in vitro (lane 2, bottom panel). Although PKC! phosphorylated activation loop 
residues of PKD1 (lane 6, bottom panel), it was incapable of phosphorylating Par-1b on 
S400 in vitro (lane 1, bottom panel). In addition, PKD1 did not phosphorylate Par-1b on 
T595, the aPKC site, in vitro (Fig. 2.4A, bottom panels).  Interestingly, S400 (Fig. 2.4A, 
upper panels) but not T595 (Fig. 2.4A, lower panels) was a site of Par-1b 
autophosphorylation (lane 1).  To determine if auto/trans phosphorylation contributed 
significantly to S400 phosphorylation in vivo, WT and mutant forms of Par-1b were 
expressed in Par-1b null MEFs (Hurov  et al., 2001).  Note that kinase-active (Fig. 2.4B, 
lane 2) and kinase-inactive (lane 3) forms of Par-1b were similarly phosphorylated on 
S400. Thus, although Par-1b is capable of phosphorylating itself on S400, additional 
cellular kinase(s) also serve this function in vivo. 
Next, siRNA was used to knockdown expression of PKD1 and PKD2 in Hela 
cells. As seen in Fig. 2.4C, stimulation of S400 phosphorylation was not observed in 
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PMA-treated cells deficient for PKD1 and PKD2 (lane 4) whereas control cells (lane 2) 
or cells incubated with scrambled siRNA (lane 3) showed a robust stimulation of S400 in 
response to PMA-treatment. Taken together, these results suggest that PMA stimulates a 
signaling pathway from nPKCs to PKD to Par-1b to regulate S400-phosphorylation and 
14-3-3 binding. 
Phosphorylation of Par-1b by aPKC induces dissociation of Par-1b from the 
plasma membrane into soluble fractions in a T595-dependent manner (Suzuki et al., 
2004).  To test the consequences of S400 phosphorylation, PMA-treated HeLa cells were 
fractionated by sequential centrifugation and membrane (P) and soluble (S) fractions 
were analyzed for endogenous Par-1b by Western blotting (Fig. 2.4D). As expected, 
phosphorylated PKD was found in membrane fractions whereas 14-3-3 proteins were 
observed in soluble fractions. Importantly, endogenous Par-1b phosphorylated on S400 
was present predominantly in soluble fractions.  
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Discussion 
In this study, we identified S400 as a novel Par-1b phosphorylation site. 
Phosphorylation of S400 was shown to regulate interactions between Par-1b and 14-3-3 
proteins and to be mediated by PKD.  Par-1b is also phosphorylated on T595 and this is 
catalyzed by atypical PKC (Hurov et al., 2004b; Suzuki et al., 2004).  Thus, Par-1b is 
regulated by two arms of the PKC pathway: one arm is indirect involving activation of 
nPKCs which, in turn, activate PKD to phosphorylate Par-1b on S400, the second arm is 
direct and involves phosphorylation of T595 by aPKCs. 
Previous studies reported that 14-3-3 binding to Par-1 either does not involve Par-
1 phosphorylation (Benton et al., 2002) or is facilitated by T595 phosphorylation (Suzuki 
et al., 2004).  Another study reported 17 new Par-1b phosphorylation sites and mutation 
of all 17 of these residues eliminated 14-3-3 binding. Surprisingly S400 was not 
identified as a site of phosphorylation in this study (Goransson et al., 2006).  Here, we 
report that mutation of the two PKC-regulated sites (S400 and T595) is sufficient to 
ablate 14-3-3 binding to Par-1b. It may be that mutation of 17 residues of Par-1b 
indirectly effected phosphorylation at S400 and this, in turn, explains the loss of 14-3-3 
binding in the Goransson et al. study (Goransson et al., 2006). 
The PKC family of protein kinases are subdivided into conventional PKCs that 
are activated by calcium, acidic phospholipids and diacylglycerol (DAG); novel PKCs  
activated by DAG and acidic phospholipids but insensitive to calcium and atypical PKCs 
that are activated, in part, by PKD1 (Newton, 1997). The PKD family consists of three 
members.  PKD1 was originally reported to be a novel PKC and was given the name 
PKCµ.  However, it was later appreciated that the PKD family distinguished itself from 
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the PKC family in amino acid composition, domain structure, regulation, and substrate 
specificity (Rykx et al., 2003). A major pathway for the activation of PKD is 
translocation to membrane compartments via binding to DAG or phorbol esters followed 
by phosphorylation of activation loop residues by the nPKCs, which are directly activated 
by PMA (Rozengurt et al., 2005). Stimulation of S400 phosphorylation by PMA 
implicated members of the PKC family as regulators of Par-1b.  However, sequences 
inclusive of and surrounding S400 do not conform to a typical PKC consensus sequence 
but rather more closely resembles that of a PKD phoshorylation site (Nishikawa et al., 
1997). The experimental evidence leading to the conclusion that PKD directly 
phosphorylates Par-1b on S400 in a nPKC-dependent manner is as follows: enhanced 
S400-phosphorylation was observed when Par-1b was co-produced with PKD1 and/or 
PKC! (Fig. 2.3A); the stimulatory effects of PKD1 and PKC! on Par-1b S400-
phosphorylation were blocked by kinase-inactive forms of each kinase (Fig. 2.3A); 
importantly kinase–inactive PKC! was unable to block the stimulatory effects of 
constitutively-active PKD1 on Par-1b S400 phosphorylation (Fig. 2.3A); PKD, but not 
nPKC, directly phosphorylated Par-1b on S400 in vitro (Fig. 2.3B) and finally, 
stimulation of S400 phosphorylation by PMA was not observed in cells deficient for 
PKD1 and PKD2 (Fig. 2.4C). Taken together this data argues that PMA stimulates 
nPKCs to activate PKD and PKD, in turn, directly phosphorylates Par-1b on S400. 
PKD functions downstream of activated G-protein coupled receptors and receptor 
tyrosine kinases that signal through phospholipase C. PKD is activated by any agent that 
activates nPKCs and, as such PKD functions to regulate a diverse set of cellular 
processes including proliferation, apoptosis, stress responses, vesicle trafficking from 
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golgi, neuronal development, and immune cell signaling (Toker, 2005; Van Lint et al., 
2002; Wang, 2006). If Par-1b is an important downstream target of PKD in each of these 
pathways, it may explain the diverse phenotypes observed in mice disrupted for Par-1b 
(Hurov and Piwnica-Worms, 2007). It has been demonstrated that the regulated cycling 
of Par-b on and off lateral membranes is critical for maintenance of apicobasal polarity in 
mammalian cells (Suzuki et al., 2004). Our study provides mechanistic insight into how 
Par-1b shuttling is regulated.  Phoshorylation of Par-1b on S400 by PKD, like 
phosphorylation of T595 by aPKC, not only promotes the binding of 14-3-3 proteins to 
Par-1b but also promotes the release of Par-1b off of cellular membranes.  Furthermore, 
these results implicate a role for PKD in regulating cellular polarity through 
phosphorylation of Par-1b. 
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Materials and Methods 
 
Cell Culture  
HeLa, HEK-293 and HCT116 cells were routinely maintained in Dulbecco's modified 
Eagle's medium (DMEM, Gibco-BRL) supplemented with 10% bovine growth serum 
(Hyclone, Logan, UT), 100 units/ml penicillin and streptomycin, and 1mM L-glutamine. 
MCF7 cells were grown in the presence of 10% FBS (Hyclone).  Par-1b null MEFs 
(Hurov  et al., 2001) were cultured in DMEM, 10% FBS (Hyclone) and 1 mM L-
glutamine, 0.2 mM nonessential amino acids, 140 mM 2-mercaptoethanol, 100 U/ml 
penicillin G and 100 µg/ml streptomycin. 
 
Plasmids and reagents 
PMA was purchased from Sigma Chemical Company (St. Louis, MO).  Purified PKC! 
and the PKC lipid activator were purchased from Upstate Cell Signaling (Lake Placid, 
NY). Sf9 cell purified HA-PKD and HA-PKD (K612W) as well as plasmids 
pcDNA3.HA-PKD1, pcDNA3.HA-PKD1(K612W),  pcDNA3.HA-PKD1 (S738ES742E) 
have been described (Storz et al., 2003; Storz et al., 2004).  Plasmids encoding 
PKC!(WT) and PKC!(KD) and Flag tagged Par-1b, Par-1b(D193N) and Par-1b(T595A) 
have been described (Cenni et al., 2002; Hurov et al., 2004a).  Substitution of alanine for 
serine at position 400 and/or threonine at position 595 was accomplished using the 
QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, LaJolla. CA). DNA 
sequencing was performed to verify the mutant sequence.  siRNAs specific for PKD1 and 
PKD2 were purchased from Dharmacon Inc. (Lafayette, CO) as well as SiGenome Smart 
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Pool reagent to Human PRKCM (PKD1) and Smart Pool reagent to Human PRKD2 
(PKD2). The control siRNA sequence was: 5’UAAGGCUAUGAAGAGAUACUU. 
Transient transfections were performed using TransIT HeLa MONSTER reagent (Mirus 
Bio Corporation, Madison, WI), with Superfect reagent (Qiagen, Valencia, CA) or with 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Par-1b null MEFs have been 
described (Hurov  et al., 2001) 
 
Antibodies and Western Blotting  
Antibodies against 14-3-3 (K19) and glutathione S-transferase (GST) were purchased 
from Santa Cruz (Santa Cruz, CA). Other antibodies used in this study were specific for 
PKD1 (Abcam or Cell Signaling Technology), PKD2 (Abcam, Cambridge. MA), 
phosphoPKD (Cell Signaling Technology, Boston, MA) and PKC! (Upstate Cell 
Signaling). Antibodies used for experiments shown in Fig. S1E include a rabbit 
polyclonal antibody specific for PKD1 raised against a NH2-MAECQNDSGEMQDP-
amide peptide (amino acids 372-385 in human PKD1), a rabbit polyclonal antibody 
specific for PKD2 was from Upstate Cell Signaling (Charlottesville, VA), and a rabbit 
polyclonal antibody specific for PKD3 from Bethyl Laboratories (Montgomery, TX). 
These antibodies are specific for the respective PKD isoenzyme and do not cross react 
with other PKD family members. Antibodies specific for Par-1b have been described 
(Hurov  et al., 2001). Antibodies specific for Par-1b phosphorylated on serine 400 were 
generated by immunizing rabbits with the phosphopeptide CQRSV-pS-ANPKQ coupled 
to keyhole limpet hemocyanin (KLH). Antibodies specific for Par-1b phosphorylated on 
T595 have been described (Hurov et al., 2004b). Flag-fusion proteins were precipitated 
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with anti-Flag M2 antibody-agarose affinity gel (Sigma Chemical Co) and detected by 
Western blotting with anti-Flag M2 monoclonal antibody (Sigma Chemical Co.).  For 
Western blotting, antibodies were diluted in 5 % milk in TBST (50 mM Tris-HCl pH 8.0, 
0.15 M NaCl, 0.02 % Tween-20), and membranes were washed 4 times in TBST after 
application of both primary and secondary antibody.  Bound primary antibodies were 
detected with horseradish peroxidase-conjugated goat anti-mouse (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA), goat anti-rabbit (Invitrogen, 
Carlsbad, CA), or donkey anti-goat (Santa Cruz) secondary antibodies, and visualized 
using the ECL reagent (GE Healthcare, Piscataway, NJ) or Super Signal West Femto 
reagent (Pierce Biotechnology, Rockford, IL). 
 
Immunoprecipitations 
Cells were lysed in MCLB (50 mM Tris-HCl pH 8.0, 0.1 M NaCl, 5 mM EDTA, 0.5 % 
NP-40, 1 mM DTT) supplemented with 1 µM microcystin-LR and protease inhibitors (2 
mM PMSF, 0.15 U/ml aprotinin, 20 µM leupeptin, and 20 µM pepstatin.).  Lysates were 
clarified by centrifugation at 16, 000 x g.  Cell lysates were pre-cleared with protein A 
agarose for 1 hour at 4 °C, then incubated with anti-FLAG agarose (Sigma Chemical Co.) 
for 1 h at 4°C.  Beads were washed four times in MCLB, and bound proteins eluted by 
boiling in SDS–PAGE sample buffer. 
 
14-3-3 Far Western Analysis 
Samples were subjected to SDS-PAGE and transferred to nitrocellulose membranes as 
for a Western blot.  Proteins bound to the membrane were denatured by incubating for at 
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least 1 h in denaturation buffer (50 mM Tris-HCl pH 8.0, 6 M guanidine-HCl, 6.25 mM 
EDTA, 1 mM DTT, 10 % glycerol, 0.05 % Tween-20), then renatured by incubating for 
at least 1 h in renaturation buffer (denaturation buffer without guanidine-HCl or DTT).  
Membranes were blocked for 1 h in 5 % milk in TBST, rinsed in TBST, then incubated 
for 2 h at room temperature or overnight at 4°C in TBST containing 0.1 µg/ml GST-14-3-
3! and ", and 1 mg/ml bovine serum albumin. GST-14-3-3 proteins were purified as 
described (Meek et al., 2004b).  Membranes were washed 4 times in TBST, then 
incubated for 1 h with anti-GST primary antibody in 5% milk / TBST.  Bound primary 
antibody was detected with horseradish peroxidase-conjugated secondary antibody, and 
visualized using ECL reagent, as for Western blotting.  
 
Co-precipitation of 14-3-3 proteins with WT and mutant forms of Par-1b  
HeLa cells at 75% confluency were transfected using Lipofectamine 2000 reagent for 24 
h.   Cells were lysed in MCLB supplemented with 1µM microcystin and protease 
inhibitors.  Lysates were clarified by centrifugation at 16,000 x g.  Cell lysates were pre-
incubated with protein A agarose for 1 hour at 4 °C, then incubated with anti-FLAG 
agarose for 1 h at 4°C.  Bound proteins were eluted by incubating 1 h with a 3X flag 
peptide (Sigma Chemical Co.).    
 
 
Kinase Assays 
Kinase reactions were carried out in the presence of 0.5 µg bacterially-purified GST-Par-
1b, GST-Par-1b (S400A), or GST-Par-1b (D160N) with 250 ng Sf9 cell purified HA-
 -53- 
PKD or HA-PKD (K612W) or with 5 ng active PKC! (Upstate Cell Signaling) and a 
buffer consisting of 12 µM ATP, 2 mM DTT, 10 mM MgCl2, and 50 mM Tris pH 7.5 
supplemented with sonicated PKC lipid activator containing phosphatidyl serine and 
diacylglycerol (Upstate Cell Signaling). Samples were incubated at room temperature for 
30 min. Reactions were terminated by the addition of SDS sample buffer followed by 
incubation for 10 min at 37oC.  
 
RNAi Experiments 
RNA interference (RNAi) was performed using protocols supplied by Dharmacon, Inc. 
siRNA duplexes were transfected into HEK293 cells using Dharmafect #2 at a final 
concentration of 10 nM.  After ~30 h cells were transfected a second time with siRNA at 
10 nM final concentration.  Cells were incubated an additional 48 h and then incubated in 
the absence or presence of 200 ng/ml PMA for 1 min.  Cells were lysed in MCLB and 
analyzed by Western blotting. 
 
Cell Fractionation 
HeLa cells were grown to near confluency on 10 cm tissue culture dishes. Cells were 
treated with 200 ng/ml PMA for 1 min prior to harvest. Cells were trypsinized and 
washed in ice cold PBS.  Cells were suspended in 800 µl of hypotonic buffer (HB: 12.5 
mM Tris pH 7.5, 1 mM EDTA, 1 mM DTT) supplemented with 5 mM NaP4PO4, 1 µM 
microcystin, 1 mM sodium orthovanadate, 2 mM PMSF, 0.15 U/ml aprotinin, 20 µM 
leupeptin, and 20 µM pepstatin for ~40 min.  Cells were dounce homogenized and when 
the majority of cells were lysed, cell lysates were centrifuged at 1000 x g for 5 min.  The 
 -54- 
resulting supernatant was transferred to a fresh tube and the pellet was washed once with 
200 µl of HB. The washed supernatant was added to the first collected supernatant (= 
total (T)). A portion of this was reserved for Western blotting and the remainder was 
centrifuged at 100,000 x g for 30 min. The supernatant was transferred to a fresh tube (= 
soluble (S) fraction) and the pellet was vortexed in 100 µl HB and recentrifuged at 
100,000 x g for 15 min.  The supernatant was added to the soluble fraction and the pellet 
(= membrane (M) fraction) was resuspended in 300 µl of MCLB supplemented with 1  
µM microcystin, 1 mM sodium orthovanadate and protease inhibitors. Fractions were 
resolved by SDS-PAGE and proteins visualized by Western blotting using Super Signal 
West Femto reagent. 
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Fig. 2.1 Par-1b is phosphorylated on serine 400 in vivo.  
(A) HeLa cells were transfected with plasmids encoding the indicated proteins using 
HeLa MONSTER reagent for 48 h. Flag-tagged Par-1b proteins were resolved by SDS-
PAGE and Western blotting was performed with an antibody specific for Par-1b 
phosphorylated on S400 (top panel).  Blots were stripped and re-probed with an antibody 
specific for the flag epitope (bottom panel).  (B) Lysates prepared from the indicated cell 
lines were resolved by SDS-PAGE and Western blotting was performed with an antibody 
specific for Par-1b phosphorylated on S400 (top panel).  Blots were stripped and re-
probed with an antibody specific for Par-1b (bottom panel). (C) Sequence alignment of 
Par-1 orthologs illustrates conservation of the S400 phosphorylation site. The mode I 14-
3-3 binding motif, the PKD phosphorylation motif and the phosphopeptide used to 
generate the pS400-specific Par-1b antibody are also indicated.  
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Fig. 2.2  Phosphorylation of Par-1b on S400 regulates 14-3-3 binding and is 
stimulated by PMA.  
(A) HEK293 cells were transfected with plasmids encoding WT Par-1b (WT), kinase-
inactive Par-1b (D193N) or a phosphorylation-site mutant of Par-1b (S400A) using 
Superfect reagent for 48 h. Lysates were resolved directly by SDS-PAGE (lanes 5-8) or 
were incubated with anti-flag agarose prior to SDS-PAGE (lanes 1-4). Western blotting 
was performed with an antibody specific for the flag epitope to detect Par-1b (top panel) 
or with an antibody specific for 14-3-3 proteins (bottom panel). Relative levels of 14-3-3 
in each precipitate were determined from Western blots using the ImageJ program and 
are indicated below the blot. (B) HEK293 cells were transfected with plasmids encoding 
the indicated fusion proteins using Superfect reagent for 48 h. Lysates were incubated 
with anti-flag agarose and precipitates were resolved by SDS-PAGE. Precipitates were 
subjected to Western blotting to monitor Par-1b levels (lanes 1-3) or to Far Western 
analysis to monitor 14-3-3 binding (lanes 4-6). (C) HeLa cells were transfected with 
plasmids encoding the indicated flag-tagged proteins using Lipofectamine 2000 for 24 h.  
Lysates were incubated with flag agarose.  Precipitates were resolved by SDS-PAGE and 
analyzed by Western blotting using the indicated antibodies. Relative levels of 14-3-3 in 
each precipitate were determined from Western blots using the ImageJ program and are 
indicated below the blot (Fig. S1C). A representative experiment is shown in panel C. (D) 
Lysates prepared from HeLa cells that had been cultured in the absence of serum for 16 h 
and then treated with vehicle (lane 1) or with 400 ng/ml PMA for 10 min. (lane 2) were 
resolved by SDS-PAGE and Western blotting was performed with pS400 antibody (top 
panel). Blots were stripped and re-probed with a Par-1b specific antibody (bottom panel). 
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(E) HEK293 cells were transfected with plasmid encoding Flag-Par-1b using Superfect 
reagent for 48 h. Cells were cultured in the absence of serum for 3 h and then treated with 
vehicle (lanes 1, 3) or with 400 ng/ml PMA for 20 min (lanes 2, 4).  Flag-tagged Par-1b 
was precipitated using anti-flag agarose and resolved by SDS-PAGE.  Flag-Par-1b was 
subjected to Western blotting to monitor S400 phosphorylation (lanes 1, 2) or to Far 
Western analysis to monitor 14-3-3 binding (lanes 3, 4). The pS400 blot was stripped and 
probed with antibody specific to the flag epitope (lanes 5, 6).  
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Fig. 2.3 Phosphorylation of Par-1b on S400 is regulated by nPKC/PKD pathway 
(A) HEK293 cells were transfected with the indicated plasmids using Superfect reagent 
for 24 h. Lysates were resolved by SDS-PAGE and subjected to Western blotting. (B) 
Kinase assays were performed in vitro with a kinase-inactive mutant of Par-1b and the 
indicated purified protein kinases. Western blotting was performed to monitor levels of 
each protein in the assay (top 3 panels) and to monitor the phosphorylation status of Par-
1b (bottom panel, lanes 1-5) and PKD1 (bottom panel, lane 6). 
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Fig. 2.4 Phosphorylation and localization of Par-1b regulated by PKD in vivo. 
(A) Kinase assays were performed in vitro with kinase-active Par-1b alone (lane 1) or in 
the presence of kinase-active (lane 2) or kinase-inactive (K612W, lane 3) PKD1. 
Reactions were resolved by SDS-PAGE and subjected to Western Blotting. The 
phosphorylation status of Par-1b was monitored using the indicated phospho-specific 
antibodies. (B) Par-1b null MEFs (Hurov et al., 2001) were transfected with plasmids 
expressing the indicated proteins using Lipofectamine 2000 for 24 h. Lysates were 
incubated with anti-flag agarose and precipitates were resolved by SDS-PAGE. 
Precipitates were subjected to Western blotting with antibodies specific for Par-1b 
phosphorylated on S400 (top panel). Blots were stripped and re-probed with Flag-specific 
antibodies (bottom panel). (C) HeLa cells were untreated, incubated with control siRNAs 
or with siRNAs specific for PKD1 and PKD2 as described in the methods section.  Cells 
were incubated for 1 min with 200 ng/ml PMA, lysed and subjected to Western blotting 
with the indicated antibodies. Relative levels of S400 phoshorylation and Par-1b protein 
are indicated above each blot.  (D) Lysates from PMA-treated HeLa cells (T) were 
fractionated into soluble (S) and membrane (M) compartments. Fractions were probed for 
the indicated proteins by Western blotting.  Arrows denote two isoforms of Par-1b. 
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Fig. 2.S1 Par-1a is phosphorylated on serine 400 in vivo.  
(A) The kinase-, UBA- and ELKL-domains of Par-1b are indicated.  Black boxes 
represent regions that are absent in spliced variants of human Par-1b. The signaling 
pathways regulating phosphorylation of S400 and T595 are indicated.  (B) HeLa cells 
were transfected with plasmid encoding flag-tagged Par-1a using Lipofectamine 2000 for 
24 h. Lysates from control cells (lane 1) or cells expressing flag-tagged Par-1a (lane 2) 
were resolved directly by SDS-PAGE. Western blotting was performed with indicated 
antibodies. (C) HeLa cells were transfected with plasmids encoding the indicated flag-
tagged proteins using Lipofectamine 2000 for 24 h.  Lysates were incubated with flag 
agarose.  Precipitates were resolved by SDS-PAGE and analyzed by Western blotting 
using the indicated antibodies. Relative levels of 14-3-3 in each precipitate were 
determined from Western blots using the ImageJ program and are indicated below the 
blot. The mean +/- SEM for five independent experiments is shown. Student’s t test was 
performed for comparisons between groups. p value designations are as follows: * 
(p<0.005), **(p<0.001). A representative Western blot is shown in Figure 2C.  (D) HeLa 
cells were transfected with plasmids encoding the indicated flag-tagged proteins using 
Lipofectamine 2000 for 24 h and then incubated with 200 ng/ml PMA for 1 min.  Lysates 
were incubated with flag agarose and precipitates were resolved by SDS-PAGE and 
analyzed by Western blotting for the indicated proteins. Relative levels of 14-3-3 in each 
precipitate were determined from Western blots using the ImageJ program and are 
indicated below the blot.  (E) HeLa cells were cultured in the absence of serum for 16 h 
and treated with vehicle (lanes 1, 3, 5) or with 400 ng/ml PMA for 10 min (lanes 2, 4, 6). 
PKD1, PKD2 and PKD3 were immunoprecipitated and samples were resolved by SDS-
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PAGE. Immunoblotting was performed with a phospho-specific antibody that recognizes 
activated PKD1. Blots were stripped and re-probed with PKD1-, PKD2- or PKD3-
specific antibodies (bottom panel). 
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Abstract 
Establishing and maintaining cellular polarity is critical for the homeostasis of 
unicellular and multicellular organisms alike. The PAR (partitioning-defective) genes 
(PAR-1–6) were identified in Caenorhabditis elegans (C. elegans) as essential 
determinants of asymmetric cell division and polarized cell growth.  Orthologs of PAR-1, 
3, 4, 5, and 6 but not PAR-2 have been identified in mammals.  The mammalian Par-1 
family is comprised of four members (Par-1a, b, c and d).  We have shown that Par-1b 
and the RING finger containing protein RNF41 bind one another.  RNF41 and Par-2 
share homology in their RING finger domain and part of their C-terminal domain 
suggesting that RNF41 may be an ortholog of Par-2. RNF41 binds the N-terminal kinase 
and ubiquitin associated (UBA) domains of Par-1b and Par-1b phosphorylates RNF41 on 
serine 254.  MCF-10A cells knocked down for RNF41 failed to form polarized acini-like 
spheroids when grown in either collagen I matrix or in Matrigel. Polarity was rescued 
when knockdown cells were engineered to express wild-type RNF41 but not the 
phosphorylation-site mutant of RNF41 encoding alanine for serine at position 254. This 
study identifies RNF41 as a novel substrate of Par-1 and demonstrates that 
phosphorylation of RNF41 by Par-1 is required for mammary epithelial cells to polarize 
when grown in three-dimensional cultures.  
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Introduction 
Epithelial cells depend on the asymmetric organization of cellular components 
along their apical- basal axis and it is the activity of these asymmetrically localized 
proteins and protein complexes that regulate polarity (Rodriguez-Boulan and Nelson, 
1989).  Par-1 encodes a serine/threonine protein kinase and is one of six Par 
(partitioning-defective) genes (Par-1, Par-2, Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, and 
Par-6) identified in a genetic screen conducted in Caenorhabditis elegans (C. elegans) 
(Kemphues et al., 1988).  The Par genes are required for the asymmetric cell division of 
the C. elegans zygote(Kemphues et al., 1988).  Orthologs of each of the C. elegans Par 
genes have been identified except for Par-2. Par-2 is a RING finger containing protein 
that co-localizes with Par-1 to the posterior pole of the C. elegans zygote and cooperates 
with other Par gene products to establish polarity during early embryonic development.   
In epithelial cells, the organization and establishment of cell polarity is dependent 
on the antagonistic relationship between Par-1 and the Par-3/Par-6/atypical protein kinase 
C (aPKC) complex.  The Par-3/Par-6/aPKC complex localizes to tight junctions and the 
integrity of this complex is required for maintaining polarity (Etienne-Manneville and 
Hall, 2003; Izumi et al., 1998; Joberty et al., 2000). Mammalian Par-1 kinase is excluded 
from tight junctions and instead localizes to basolateral membranes (Bohm et al., 1997). 
Par-1 phosphorylates Par-3 to exclude it from tight junctions (Benton and St Johnston, 
2003; Hurd et al., 2003) whereas aPKC in complex with Par-3/Par-6 phosphorylates Par-
1 on T595 to displace it from membranes (Chen et al., 2006; Hurov et al., 2004; Suzuki et 
al., 2004). In mammals there are four Par-1 family members: Par-1a (C-TAK1/MARK3), 
Par-1b (EMK/MARK2), Par-1c (MARK1) and Par-1d (MARKL1, MARK 4) (Drewes et 
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al., 1997; Espinosa and Navarro, 1998; Hurov  et al., 2001; Inglis et al., 1993; Kato et al., 
2001; Muller et al., 2001; Peng et al., 1998). 
A proteomic screen employing tandem affinity purification (TAP) followed by 
tandem mass spectrometry identified a complex of proteins that associate with one of the 
human Par-1 orthologs (Par-1d/MARK4) (Brajenovic et al., 2004).  This screen identified 
both known (aPKC and 14-3-3) and novel Par-1 interacting proteins (Brajenovic et al., 
2004).  Of particular interest was the identification of the RING finger E3 ubiquitin ligase 
RNF41 as a Par-1d interacting protein.  RNF41 is also known as NRDP1 (neuregulin 
receptor degradation protein-1) based on its role in facilitating the ubiquitin-mediated 
proteolysis of ErbB3(Diamonti et al., 2002).  RNF41 contains an N-terminal RING 
domain, two zinc-finger domains (B-Boxes), a coiled-coil domain, and a C-terminal 
domain that binds to various substrates (Abdullah et al., 2001; Bouyain and Leahy, 2007; 
Diamonti et al., 2002; Qiu and Goldberg, 2002).   
RNF41 has been shown to regulate the steady-state levels of ErbB3 and ErbB4 
but not epidermal growth factor receptor (EGFR, ErbB1) or ErbB2 (Her2/neu). RNF41 
associates with ErbB3 and ErbB4 independently of receptor stimulation (Diamonti et al., 
2002; Qiu and Goldberg, 2002) and elicits ligand-independent ErbB3 ubiquitination and 
degradation (Qiu and Goldberg, 2002).  Importantly a concomitant reduction in ErbB3 
levels and neuregulin-1 (NRG1) growth factor signaling are observed when RNF41 is 
overproduced whereas ErbB3 accumulates and NRG1 growth factor signaling is 
enhanced when RNF41 is knocked down or a ligase-deficient (dominant-negative) 
mutant is expressed (Yen et al., 2006).  Finally, decreased RNF41 levels in tumors 
correlates with higher levels of ErbB3 in both an in vivo transgenic mouse model of 
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ErbB2-induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et 
al., 2006).   
In addition to its role in regulating NRG1 growth factor signaling by modulating 
ErbB3 levels, RNF41 also regulates ligand-independent expression of the interleukin-3 
and erythropoietin cytokine receptors (Sausville et al., 2001) by controlling receptor 
degradation and shedding (Wauman et al.) and RNF41 regulates Toll-like receptor 
(TLR)-mediated responses through ubiquitination of MyD88 and TBK1(Singh et al., 
2009). Finally, RNF41 has been implicated in the ubiquitin-mediated proteolysis of two 
ubiquitin ligases. These include the inhibitor of apoptosis BRUCE and PARKIN, a 
protein involved in the onset of Parkinson's disease (Qiu et al., 2004; Zhong et al., 2005).   
Although several targets of RNF41 have been identified, very little is known 
regarding how RNF41 itself is regulated.  RNF41 is subject to auto-ubiquitination and 
proteolysis and this is counterbalanced by the activity of USP8, a deubiquinating enzyme 
(Cao et al., 2007; Wu et al., 2004).  In this study, we demonstrate that RNF41 is regulated 
by the Par-1 polarity kinase and identify a novel role for RNF41 in regulating epithelial 
cell polarity. 
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Results 
RNF41 co-precipitates with Par-1b. 
A proteomic screen employing tandem affinity purification (TAP) followed by 
tandem mass spectrometry identified RNF41 in a complex of proteins that associate with 
Par-1d (MARK4) (Brajenovic et al., 2004). To determine if RNF41 interacted with a 
second human Par-1 ortholog, HeLa and HEK 293T cells were transfected with control 
plasmid (-), plasmid encoding human Flag-tagged CHK2 as a negative control or plasmid 
encoding Flag-tagged Par-1b.  Lysates were prepared and incubated with Flag agarose 
followed by Western blotting.  As seen in Fig. 3.1A, endogenous RNF41 was detected in 
Par-1b (lanes 3 and 6) but not in control (lanes 1, 2, 4, 5) precipitates. Two 
electrophoretic forms of RNF41 are present in HeLa and HEK 293T cells.   
Members of the Par-1 family are characterized by having a conserved amino-
terminal kinase domain, followed by a ubiquitin-associated (UBA) domain, a divergent 
region of unknown function (spacer) and ending with a conserved region of about 100 
amino acids known as the ELKL domain because it terminates with the sequence 
glutamate-leucine-lysine/asparagine-leucine (Fig. 3.1B) (Inglis et al., 1993).  Par-1b 
deletion mutants that express only the amino-terminal domain or C-terminal domain were 
expressed in cells to identify regions of Par-1b important for interactions with RNF41.  
As seen in Fig. 3.1C, endogenous RNF41 co-precipitated with full length (FL) Par-1b 
(lane 2) as well as the Par-1b mutant encoding the amino terminus and UBA domain (N-
UBA, lane 3).  Removal of the UBA domain significantly reduced RNF41 binding (lane 
5) and RNF41 did not associate with the C-terminal domain of Par-1b (lanes 4 and 6).   
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Par-1b phosphorylates RNF41 on S254 in vitro and RNF41 is phosphorylated on 
S254 in vivo. 
 To determine if RNF41 is a substrate of Par-1b, kinase assays were performed in 
vitro in conjunction with two-dimensional tryptic phosphopeptide mapping.  RNF41 was 
phosphorylated by Par-1b in vitro (Fig. 3.2A) and this occurred on one or more serine 
residues (Fig. 3.2B).  Mapping studies revealed several phosphopeptides and substitution 
of alanine for threonine at position 254 resulted in the disappearance of a single 
phosphopeptide (Fig. 3.2C) suggesting that Par-1b phosphorylates RNF41 on S254 in 
vitro.  To confirm that Par-1b phosphorylates RNF41 on S254 in vitro and that RNF41 is 
phosphorylated on S254 in vivo, a phosphospecific antibody recognizing RNF41 only 
when it is phosphorylated on S254 was generated (Fig. 3.2D). RNF41 consists of an 
amino terminal RING domain followed by a B box, a coiled-coil domain and a C-
terminal region that mediates interactions between RNF41 and ErbB3 (Receptor binding 
domain) (Fig. 3.1B).  Mutation of two residues within the RING domain (cysteine (C) 34 
and histidine (H) 36) ablates the E3 ubiquitin ligase activity of RNF41 (Qiu and Goldberg, 
2002).  Due to the ability of RNF41 to auto-ubiquitinate and promote its own 
proteosomal degradation, we generated a ligase deficient mutant of RNF41 encoding 
serine for C34 and glutamine for H36 (denoted !CH) in order to produce adequate levels 
of RNF41 in vivo.  As seen in Fig. 3.2E, the pSer254 antibody recognized ectopic RNF41 
(lane 2) and phosphorylation of S254 increased when RNF41 was co-produced with wild-
type Par-1b in vivo (lane 3).  In contrast, phosphorylation of RNF41 on S254 was reduced 
in cells expressing kinase-inactive Par-1b (lane 4). Mutation of serine 254 eliminated 
recognition of RNF41 by the phosphospecific antibody under similar conditions (lanes 5-
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7).  These results demonstrate that the antibody is specific for RNF41 when it is 
phosphorylated on S254 and that ectopically expressed RNF41 is phosphorylated on 
S254 in vivo.  Furthermore, the ability of kinase-active Par-1b to enhance S254 
phosphorylation and kinase-inactive Par-1b to decrease S254 phosphorylation suggests 
that phosphorylation of RNF41 on S254 is regulated in vivo by Par-1b.  
 
Phosphorylation of endogenous RNF41 on S254 increases as MCF-10A cells polarize 
in 3D culture. 
We were unable to detect phosphorylation of endogenous RNF41 on S254 when 
cells were grown in two-dimensional (2D) cultures (Fig. 3.3D, lane 1 and data not 
shown).  Given the critical role played by Par proteins in establishing and maintaining 
apical-basal polarity, we investigated the phosphorylation status of both RNF41 and Par-
1b in mammary epithelial cells (MCF-10A) grown in 3D cultures.  MCF-10A is a 
spontaneously immortalized but untransformed mammary epithelial cell line. When 
grown in 3D cultures, MCF-10A cells form polarized acini-like spheroids (Debnath et al., 
2003).  Parental MCF-10A cells formed normal acinar architecture along with a hollow 
lumen over a 20 day period when cultured in collagen I matrix and Matrigel (Fig. 3.3A).  
Serial confocal cross sections of an acinus were stained with To-Pro-3 to detect nuclei 
and antibody against either E-cadherin to detect adherins junctions; Alpha 6- Integrin to 
detect basolateral membranes; GM130 to detect golgi at the apical surface; Laminin V to 
detect basement membrane; and Flag epitope to detect ectopically expressed RNF41. The 
results demonstrate that normal acinar architecture is formed under our culture conditions 
and that cells are able to secrete Laminin V to form a basement membrane (Fig 3.3B,C).  
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Spheroids were also isolated at various times during the 3D culturing period and 
subjected to Western blotting.  As seen in Fig. 3.3D, enhanced phosphorylation of Par-1b 
on both S400 and T595 was observed in 3D cultures (lanes 2-5) relative to the 2D 
cultures (lane 1). Two electrophoretic forms of RNF41 were detected in MCF-10A cells 
and the faster migrating form was phosphorylated on S254 in cells grown in 3D (lanes 2-
5) but not 2D (lane 1) cultures. 
 
RNF41 is required for polarization of MCF-10A cells in 3D cultures. 
 Knockdown experiments were conducted to determine if RNF41 is required for 
MCF-10A cells to polarize into acini-like spheroids in 3D cultures. We employed a 
lentiviral vector that concurrently knocks down and rescues expression of a target gene in 
the same cell (Feng et al., 2010).  Lentiviral vectors encoding shRNAs specific for 
luciferase (shLuc) as a control or shRNA specific for sequences within the 3’UTR of 
RNF41 (shRNF41) were generated.  In addition, vectors simultaneously expressing 
shRNF41 with the coding regions of either RNF41 (WT) or RNF41 (S254A) with a C-
terminal flag epitope followed by six histidines (FlagHis6) were generated.  In this way 
we could determine whether phenotypes observed upon knockdown of RNF41 could be 
rescued by expression of either wild-type RNF41 or the S254A mutant of RNF41.  
The maximum knockdown of RNF41 we were able to achieve in MCF-10A cells 
was ~ 50%. In the experiment shown in Fig. 3.4B, shRNA treatment resulted in a 48% 
knockdown of RNF41 (lane 2). The ectopically produced tagged form (FlagHis6) of 
RNF41 co-migrated with the slower electrophoretic form of endogenous RNF41 and as 
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seen in Fig. 3.4B expression of WT and mutant forms of RNF41 (lanes 3-5) restored 
RNF41 levels in knockdown cells to approximately those detected for endogenous 
RNF41 in control cells (lane 1).  Despite only achieving a 50% knockdown of RNF41, 
dramatic effects were observed when MCF-10A were cultured in 3D.  As seen in Fig. 
3.4A, cells expressing RNF41 shRNA formed abnormal architecture after growing for 20 
days in collagen matrix or Matrigel.  Cells expressing RNF41 shRNA and grown in 
collagen matrix were not able to establish apical-basal polarity or adherins junctions (Fig. 
3.4A-E).  Furthermore, the polarity defect was rescued when wild-type RNF41 but not 
the S254A mutant of RNF41 was expressed in MCF-10A cells knocked down for RNF41 
(Fig. 3.4A-E) suggesting that phosphorylation of RNF41 on S254 is essential for 
establishing apical-basal cell polarity.  
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Discussion 
In this study, we identified RNF41 as a novel substrate of the Par-1 polarity 
kinase and discovered a role for RNF41 in regulating epithelial cell polarity.  The Par-1 
protein kinase regulates cell polarity in worms, flies, frogs and mammals (Bohm et al., 
1997; Cohen et al., 2004; Cohen and Musch, 2003; Cox et al., 2001; Muller et al., 2001; 
Ossipova et al., 2005; Shulman et al., 2000; Sun et al., 2001; Tomancak et al., 2000).  In 
order to identify Par-1 binding proteins, mammalian Par-1 orthologs were used as bait in 
a Tandem Affinity Purification (TAP) screen (Brajenovic et al., 2004).  The RING finger 
containing E3 ubiquitin ligase RNF41/NRDP1 was found in Par-1d complexes.  
Mammalian orthologs of 5 out of 6 C. elegans Par genes have been identified.  The 
exception is Par 2, which encodes a RING finger containing protein that co-localizes 
with Par-1 in the C. elegans zygote.  Par-2 and RNF41 share homology in their RING 
finger and C-terminal domains leaving open the interesting possibility that RNF41 is a 
Par-2 ortholog.  Here we show that human RNF41 binds to the amino terminal domain of 
human Par-1b. This region contains both the kinase and UBA domains of Par-1b and 
deletion of the UBA negatively impacted binding of RNF41 to Par-1b.  Since RNF41 
undergoes ubiquitination, this may indicate that a ubiquitinated form of RNF41 binds to 
the UBA domain of Par-1b. 
In the early C. elegans embryo, Par-1 is among several partitioning-defective 
mutants that disrupt asymmetric cell division, blastomere cell fate, localization of P 
granules, and mitotic spindle orientation (Kemphues et al., 1988; Kirby et al., 1990).  
Some of the mutations are within the  kinase domain of Par-1, indicating  kinase activity 
is necessary for its polarity function(Guo and Kemphues, 1995).  Of the reported Par-1 
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substrates, only Par-3 is known to play a role in regulating polarity.  Par-3 in complex 
with Par-6 and aPKC localizes to tight junctions and the integrity of this complex is 
required for maintaining polarity (Etienne-Manneville and Hall, 2003; Izumi et al., 1998; 
Joberty et al., 2000).  Par-1 phosphorylates Par-3 to exclude it from tight junctions and 
this, in turn disrupts epithelial cell polarity(Benton and St Johnston, 2003; Hurd et al., 
2003).  
Here we identify a second substrate of Par-1 (RNF41) that also plays a role in 
regulating cell polarity.  Par-1 phosphorylates RNF41 on S254, a site that is conserved in 
mammals and frogs but not in flies or the C. elegans Par-2 protein.  MCF-10A cells 
knocked down for RNF41 failed to polarize when grown in either collagen I matrix or 
Matrigel.  Interestingly, 50% knockdown of RNF41 was sufficient to prevent MCF-10A 
cells from forming polarized acini-like spheroids in 3D culture.  Polarity could be rescued 
if WT RNF41 was expressed in knockdown cells.  Phosphorylation of RNF41 on S254 
was observed to increase as MCF-10A cells polarized in 3D cultures and expression of 
the S254A mutant of RNF41 failed to rescue the polarity defect of RNF41-deficient 
MCF-10A cells. These results indicate that phosphorylation of S254 is important for the 
polarity function of RNF41.   
Serine 254 resides within the C-terminus of RNF41, and this region of RNF41 has 
been shown to bind to both targets of RNF41 (ErbB3 and BRUCE)(Diamonti et al., 2002; 
Qiu et al., 2004) and regulators of RNF41 (USP8) (Wu et al., 2004). USP8 is a 
deubiquitinating enzyme that binds to RNF41 and stabilizes it through deubiquitination.  
Serine 254 lies within the USP8 binding domain and also neighbors residues involved in 
ErbB3 binding (Avvakumov et al., 2006; Bouyain and Leahy, 2007).  Future experiments 
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will be directed at determining if phosphorylation of RNF41 on S254 regulates its 
interactions with USP8 and ErbB3. 
Preliminary studies indicate that ectopic RNF41 localizes to basolateral 
membranes in polarized MCF-10A cells grown in 3D cultures whereas a significant 
fraction of the S254A mutant protein appears to reside in the cytoplasm of the same cells.  
Future experiments will also be directed at determining if S254 phosphorylation regulates 
the intracellular localization of RNF41.  The failure of the S254A mutant of RNF41 to 
localize properly or to bind to key substrates would account for its failure to rescue 
polarity in RNF41 deficient MCF-10A cells.  
The establishment and maintenance of cell polarity is an essential property 
governing organismal homeostasis and loss of polarity is a common feature of 
transformed cells. For example, the polarity proteins Scribble, lethal giant larvae (LGL) 
and discs large (DLG) were isolated as tumour-suppressor mutations in Drosophila 
melanogaster, based on the distinctive ‘giant larvae’ phenotype of zygotic mutant 
animals(Bilder, 2004).  Little is known about their roles in human disease, but the loss or 
decreased expression of human homologues of Scribble and LGL has been found in 
colorectal cancers and malignant melanoma (Gardiol et al., 2006).  RNF41 is an E3 
ubiquitin ligase that regulates steady state levels of ErbB3 (Diamonti et al., 2002).  ErbB3 
is overexpressed in a subset of breast cancers. There is a correlation between decreased 
levels of RNF41 and increased levels of ErbB3 in a transgenic mouse model of ErbB2-
induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et al., 
2006).  It has been assumed that higher levels of active ErbB3 signaling is the major 
contributing factor driving tumorigenesis under these conditions.  Our study suggests that 
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disruption of polarity due to RNF41 loss may also be a contributing factor driving 
tumorigenesis.  
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Materials and Methods 
 
Cell culture.  HeLa cells were routinely maintained in DMEM (Gibco-BRL) 
supplemented with 10% Bovine Growth Serum (HyClone), 100 units per mL of penicillin 
and streptomycin, and 1 mM L-glutamine. HEK293T cells were grown in the presence of 
10% FBS (HyClone).  MCF-10A cells were maintained in DMEM/F12 (Invitrogen) 
supplemented with 5% Horse Serum (Invitrogen), 20 ng/ml Epidermal Growth Factor 
(EGF), 0.5 mg/ml Hydrocortisone, 100 ng/ml Cholera Toxin, 10µg/ml Insulin, and 100 
units per mL of penicillin and streptomycin.     
 
Cloning and mutagenesis.  The Flag3-Par-1b N-Term, C-Term, N-UBA, and C-UBA 
deletion mutants were cloned by PCR from the pFLAG3-CMV-10-Par-1b plasmid 
(Watkins et al., 2008) and ligation into pFLAG3-CMV-10 plasmid (Sigma Chemical Co). 
GST-RNF41 was cloned by PCR from the pCDNA3.1-RNF41-Flag plasmid (Diamonti et 
al., 2002) and ligation into the pGex2T vector (GE Healthcare).  The 
pFLRU6RNF41shRNA-cmv-MCS-FH plasmid was generated by PCR.  First, PCR of the 
U6 promoter from the pFLRU6Luc-cmv-MCS-FH plasmid was performed followed by 
PCR of the RNF41shRNA sequence targeted against the 3’UTR of RNF41 
(5’GCCACATTGTTGGCAATTTAA 3’).  The final PCR was performed with the U6 
promoter and RNF41shRNA template generated in the previous step in order to create a 
U6-RNF41shRNA fusion.  The fusion PCR product was ligated into the Xba I and Xho I 
restriction sites of the pFLRcmv-MCS-FH plasmid.  The pFLRU6RNF41shRNA-
cmvRNF41-FlagHis6-FH (WT and S254A) plasmids were generated by PCR of RNF41 
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(WT and S254A) from the appropriate pCDNA3.1-RNF41-Flag plasmid and inserted into 
the pFLRU6RNF41shRNA-cmv-MCS-FH plasmid.  The RNF41-Flag C34S/H36Q 
(!CH), RNF41-Flag C34S/H36Q/S254A, and GST-RNF41 S254A mutants were 
generated by using the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene).  
The sequences of all constructs were verified by sequencing. 
 
Plasmids.  Plasmids encoding Flag3-Par-1b, Flag3-Par-1b (D193N) (KD), GST-Par-1b 
(Hurov et al., 2004) and pCDNA3.1-RNF41-Flag have been described (Diamonti et al., 
2002).  The pFLRU6Luc-CMV-MCS-FH and pFLRCMV-MCS-FH plasmids were a 
generous gift from Dr. Greg Longmore (Washington University in St. Louis).  
 
Transient transfections. Transient transfections were performed using Lipofectamine 
2000 reagent according to the recommendations of the manufacturer (Invitrogen).  Cells 
were harvested 24 h post transfection.  
 
MCF-10A-derived cell lines.  HEK293T cells were plated at 8 x 105 cells/6 cm dish the 
day before transfection.  The next day, cells were transfected with a mixture of 1 µg viral 
DNA encoding the gene of interest and 1 µg pHR’8.2deltaR packaging plasmid at a ratio 
of 8:1 with pCMV-VSV-G envelope plasmid using Mirus LTR1 transfection reagent 
(Mirus).  MCF-10A cells were plated at 1 x 106 cells/10 cm dish the day before infection 
with the lentivirus.  After HEK293T cells were transfected with viral DNA for 48 h, 
target MCF-10A cells were infected in the presence of 10 µg/ml protamine sulfate for 4 h 
and then the virus was removed and media replaced.  Infected cells were allowed to 
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recover for 24 h and then were re-infected with lentivirus.  Infected cells were trypsinized 
and plated in media containing 1 µg/ml puromycin 48 h after the first infection with 
lentivirus.  RNF41 protein expression of selected cells was measured by Western blot. 
 
Antibodies and Western blotting.  Antibodies specific for RNF41 (Bethyl), Flag M2 
(Sigma Chemical Co.), Alpha Tubulin (Sigma Chemical Co.), and GAPDH (IMGENEX) 
were purchased.  Par-1b was detected with ascites made from a monoclonal antibody that 
has been previously described (Hurov  et al., 2001).  Par-1b protein phosphorylated on 
S400 or T595 was detected using previously described phospho-specific antibodies 
(Hurov et al., 2004; Watkins et al., 2008).  The antibody specific for RNF41 
phosphorylated on serine 254 was generated by immunizing rabbits with the 
phosphopeptide ENAHER-pS-WPQGLATC, coupled to keyhole limpet hemocyanin 
(KLH).  Par-1b fusion proteins were precipitated with anti-Flag M2 antibody-agarose 
affinity gel (Sigma Chemical Co.) and detected by Western blotting with anti-Par-1b 
ascites.  RNF41-FlagHis6 fusion protein was precipitated with anti-Flag M2 antibody-
agarose affinity gel (Sigma Chemical Co.) and detected by Western blotting with anti-
Flag M2 monoclonal antibody (Sigma Chemical Co.).  Indirect immunofluorescence was 
performed with FlagM2 (Sigma Chemical Co.), GM130 (BD Biosciences), Alpha6-
Integrin (Millipore), E-cadherin (BD Biosciences), and Laminin V (Millipore) antibodies. 
 
Immunoprecipitation.  HeLa and HEK293T cells were transfected with the indicated 
plasmids using Lipofectamine 2000 reagent (Invitrogen) at 75% confluence.  Cells were 
grown for 24 h before washing in ice-cold phosphate-buffered saline (PBS) once and 
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harvesting in ice-cold mammalian cell lysis buffer (MCLB: 50 mM Tris HCl pH 8.0, 100 
mM NaCl, 2 mM DTT, 5 mM EDTA, 0.5% NP-40, 1 µm microcystin, 1 mM sodium 
orthovanadate, 2 mM PMSF, 0.15U/ml aprotinin, 20 µm leupeptin, and 20 µm pepstatin).  
One mg of total cell lysate was used for the indicated immunoprecipitations (IP). M2 
Flag-agarose (Sigma Chemical Co.) (1:1 slurry in MCLB, 10 µl) was used to 
immunoprecipitate Flag3-Par-1b and RNF41-FlagHis6 proteins for 1 h at 4oC. 
Immunoprecipitations were washed 6 times with ice-cold MCLB before boiling in SDS-
PAGE sample buffer and loading on an SDS gel. 
 
Expression and purification of proteins in bacteria.  JM109 cells were transformed 
with a plasmid encoding GST-RNF41. Cultures were grown at 37oC to an A600 of 0.6, 
and isopropyl-1-thio-!-D-galactopyranoside (IPTG) was added to a final concentration of 
0.5 mM.  After growing for an additional 4 h at 30oC, cells were pelleted by 
centrifugation.  Cell pellets were washed with PBS buffer and resuspended in STE (100 
mM NaCl, 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) supplemented with 2 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.15 unit/ml aprotinin, 20 µM leupeptin, 20 µM 
pepstatin (referred to as 1 x protease inhibitors), and 1.0 mg/ml lysozyme.  After rocking 
at 4oC for 20 min, Sarkosyl was added to a final concentration of 1.5%, and lysis was 
accomplished by sonication.  Lysates were clarified by centrifugation, and Triton X-l00 
was added to a final concentration of 2%.  Proteins were precipitated with GSH agarose 
and washed twice in STE, twice in LiCl buffer (0.5 M LiCl, 50 mM Tris-HCl, pH 8.0), 
and twice in 50 mM Tris-HCl, pH 7.4.  GST-fusion proteins were eluted with 20 mM 
glutathione in 50 mM Tris-HCl (pH 7.4), and the concentration of each GST-fusion 
 -90- 
protein was estimated by comparison to known Bovine Serum Albumin (BSA) standards 
after SDS- PAGE and Coomassie Blue staining. 
 
To express GST-Par-1b in bacteria, the E. coli strain JM109 was transformed with GST-
Par-1b and cultures were grown at 37oC until reaching an A600 of ~0.6.  Cells were 
induced with 100 µM IPTG, grown at 28oC for 11 h, collected by centrifugation and 
resuspended in STE buffer supplemented with 1x protease inhibitors and 1.0 mg/ml 
lysozyme.  After rocking at 4oC for 20 min, cells were lysed by sonication and 
centrifuged at 3,000 x g for 10 min.  Proteins were precipitated with GSH agarose and 
washed as described above.  Finally, precipitated proteins were washed with incomplete 
kinase buffer (50 mM Tris-HCl, pH 7.5, 12.5 mM MgCl2, 1 mM DTT).  
 
Kinase assays.  Recombinant GST-Par-1b bound to GSH agarose was incubated with 5 
µg of recombinant GST-RNF41 in complete kinase buffer (50 mM Tris-HCl, pH 7.5, 
12.5 mM MgCl2, 1 mM DTT, 440 µM ATP, and 7 µCi !32P ATP [>4000 Ci/mmol]) at 
37oC for 30 min. Samples were boiled, resolved by SDS-PAGE, and transferred to 
nitrocellulose.  
 
Mapping studies. The nitrocellulose containing radiolabeled GST-RNF41 was blocked 
with 0.5% polyvinylpyrrolidone (PVP-40) in 100 mM acetic acid for 30 min at 37oC, 
followed by washing 6 times with water. Radiolabeled GST-RNF41 was digested in a 
solution containing 0.2 mg of trypsin (Worthington) per ml in 50 mM ammonium 
bicarbonate. Tryptic phosphopeptides were separated in the first dimension by thin layer 
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chromatography at pH 1.9 and in the second dimension by ascending chromatography in 
a buffer consisting of n-butanol-pyridine-acetic acid-water in a ratio of 75/50/15/60.  For 
PAA analysis, washed tryptic labeled peptides were boiled in 6N hydrochloric acid for 90 
min, followed by washing six times with water (van der Geer and Hunter, 1994). 
 
Three-dimensional (3D) cultures.  Each well of a 6-well plate was coated with 500 µl of 
a mixture of collagen type 1 (BD Biosciences), 1N Sodium Hydroxide, Horse Serum 
(Invitrogen), 5x DMEM (Sigma Chemical Co.) and sterile water at a 
1.0/0.02/0.08/0.3/0.3 ratio.  The collagen coating was allowed to polymerize in a tissue 
culture incubator for 30 min at 37oC.  MCF-10A cells or transduced MCF-10A cells 
selected with puromycin were trypsinized and 7.49 x 104 cells were added to mixture 
consisting of  collagen type 1, 1N Sodium Hydroxide, Horse Serum, 5x DMEM and 
sterile water mixture (1.0/0.02/0.08/0.3/0.06 ratio) on ice.  The cell/collagen mixture was 
gently mixed so that cells were in suspension and 1 ml of the mixture was added to each 
of 3 wells of the 6-well plate.  The cell/collagen mixture was allowed to polymerize in a 
tissue culture incubator for 1 h at 37oC and then 2 ml of media with or without 1 µg/ml 
puromycin was added to each well.  Cells were harvested after 8, 10, 14 or 20 days in 
culture.  Cells were harvested by pooling each piece of polymerized collagen and cells 
from each of 3 wells and incubating them in 20 mg/ml Collagenase A (Roche) in PBS for 
5 min at 37oC.  The cells were washed three times with ice-cold PBS and either spotted 
on a glass slide for analysis by indirect immunofluorescence microscopy or lysed in ice-
cold MCLB followed by Western blotting. 
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For cells grown in Matrigel (BD Biosciences), each well of a 6-well plate was coated 
with 300 µl of Matrigel and the coating was allowed to polymerize in a tissue culture 
incubator for 30 min at 37oC.  MCF-10A cells or transduced MCF-10A cells selected 
with puromycin were trypsinized and 6 x105 cells were suspended in 1.2 ml matrigel per 
well and plated.  The cell/Matrigel mixture was allowed to polymerize in a tissue culture 
incubator for 1 h at 37oC and then 2 ml of media with or without 1 µg/ml puromycin was 
added to each well.  Cells were harvested after 8, 10, 14 or 20 days in culture.  Cells were 
harvested by washing each well twice with 2 ml ice-cold PBS and then adding 6 ml of 
ice-cold 5mM Ethylenediaminetetraacetic acid (EDTA) in 1X PBS.  Cells were rocked in 
buffer containing EDTA/PBS at 4oC until all of the Matrigel was dissolved.  The cells 
were washed three times with ice-cold PBS and either spotted on a glass slide for analysis 
by indirect immunofluorescence microscopy or lysed in ice-cold MCLB and analyzed by 
Western blotting. 
       
Indirect immunofluorescence microscopy.  MCF-10A cells grown in 3D culture were 
spotted onto microscope slides and fixed with 4% Paraformaldehyde (PFA) in PBS for 20 
min at room temperature.  Slides were washed two times with room temperature PBS and 
three times (10 min each wash) at room temperature in 100 mM glycine in PBS.  Fixed 
cells were blocked in IF blocking solution (10% normal goat or donkey serum, 0.2% 
Triton X-100, 0.1% BSA (radioimmunoassay grade, Sigma Chemical Co.) and 0.05% 
Tween 20 in PBS, pH 7.4) for 1.5 h at room temperature in a humidified chamber.  Fixed 
cells were stained with primary antibody diluted in IF buffer (IF blocking solution 
without 10% normal goat or donkey serum) for 2 h at room temperature in a humidified 
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chamber.  Slides were washed three times for 20 min in IF buffer in a Coplin jar at room 
temperature with gentle shaking.  Cells were then incubated with a secondary antibody 
(Alexa488 or Alexa594) diluted in IF buffer for 45 min at room temperature in a 
humidified chamber.  Slides were washed once with IF buffer for 20 min and then two 
times with PBS for 10 min at room temperature with gentle shaking.  Finally, cells were 
stained with 1 µM TO-PRO-3 Iodide (Invitrogen) for 10 min at room temperature in a 
humidified chamber, slides were washed once with PBS for 10 min with gentle shaking, 
and slides were mounted with Prolong Antifade mounting media (Molecular Probes).  
Images were obtained using an Olympus FV-500 confocal microscope with a 60x water 
objective.  Images were processed using the Olympus FLUOVIEW Ver.2.1a Viewer 
software. 
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Fig. 3.1  RNF41 binds to the amino terminus of Par-1b. 
(A) HeLa (lanes 1-3) and HEK293T (lanes 4-6) cells were transfected with plasmids 
encoding Flag3-Chk2 (lanes 2 and 5) or Flag3-Par-1b (lanes 3 and 6) for 24 h.  Cells were 
harvested and lysates resolved by SDS-PAGE or incubated with anti-Flag agarose before 
SDS-PAGE.  Total lysates and immunoprecipitations were analyzed by Western blotting 
using the indicated antibodies. (B) Schematic representation of Par-1b and RNF41 
proteins.  Protein domains, point mutations and deletion mutants are indicated. (C) 
HEK293T cells were transfected with plasmids encoding Flag3-Par-1b full length (FL) 
(lane 2), N-UBA (lane 3), C-UBA (lane 4), N-Term (lane 5), or C-Term (lane 6) deletion 
mutants.  Cells were harvested 24 h later and lysates were resolved by SDS-PAGE or 
were incubated with anti-Flag agarose prior to SDS-PAGE.  Total lysates and 
immunoprecipitations were analyzed by Western blotting using the indicated antibodies. 
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Fig. 3.2  Phosphorylation of RNF41 by Par-1b.  
(A, B, C) Bacterially produced GST-Par-1b was incubated in the absence or presence of 
bacterially produced GST-RNF41 and kinase assays were performed in vitro.  
Radiolabeled reaction products were resolved by SDS-PAGE (panel A) and 
phosphotryptic peptides were subjected to phosphoamino acid analysis (PAA analysis) 
(panel B).  A kinase assay was also performed with GST-Par-1b and GST-RNF41 (WT 
or S254A) and two-dimensional phosphopeptide mapping (panel C) was performed.  
Arrows indicate the direction of electrophoresis (x axis) and chromatography (y-axis).  
(D) Kinase assays were performed in vitro using GST-RNF41 WT (lanes 1 and 3) or 
GST-S254A (lanes 2 and 4) with (lanes 3 and 4) or without GST-Par-1b (lanes 1 and 2).  
Proteins were resolved by SDS-PAGE and detected by Western blotting using the 
indicated antibodies.  (E) Lysates prepared from mock-transfected HEK293T cells (lane 
1) or from HEK293T cells expressing RNF41-Flag!CH (lanes 2-4) or RNF41-FlagS254A 
!CH (lanes 5-7) with Flag3-Par-1b WT (lanes 3 and 6) or Flag3-Par-1b KD (lane 4 and 7) 
were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. 
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Fig. 3.3 RNF41 is phosphorylated on S254 as MCF-10A cells polarize in 3D cultures. 
(A) MCF-10A cells were grown in collagen I matrix or in Matrigel and harvested at the 
indicated times. (B,C) Cells described in panel A were fixed and proteins were detected 
using indirect immunofluorescent staining and confocal microscopy. (D) MCF-10A cells 
were grown in 2D or 3D culture.  Cells grown in 3D culture were harvested at the 
indicated times.  Cell lysates were resolved by SDS-PAGE and immunoblotted with the 
indicated antibodies. 
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Fig. 3.4 RNF41 is required for MCF-10A cells to polarize in 3D cultures. 
(A)  MCF-10A cells expressing either lucshRNA, RNF41shRNA, RNF41shRNA + 
RNF41WT-Flag His6, or RNF41shRNA + RNF41S254A-Flag His6 were grown in plastic 
culture dishes (2D), in collagen I matrix, or in Matrigel.  Cells were harvested and lysates 
were resolved by SDS-PAGE (panel C lanes 1-5) or incubated with anti-Flag agarose 
prior to SDS-PAGE (panel C, subpanel *).  Total lysates and immunoprecipitates were 
analyzed by Western blotting using the indicated antibodies. (D, E) Cells described in 
panel A were grown in collagen I matrix, and harvested after 20 days.  Cells were fixed 
and proteins were detected using indirect immunofluorescent staining and confocal 
microscopy. (F) The number of polarized acini-like spheroids were counted in 3 separate 
experiments (n = 3).  A one way ANOVA was performed and p<0.0001 (****).  A 
Tukey’s multiple comparison posttest showed p values as described on the graph (*** = 
p<0.001, ** = p<0.01). 
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Contributions: 
 Results of my study of the protein levels of glycogen synthase (GS) and 
phosphoryalted glycogen synthase (pGS) in the liver of fasted Par-1a -/- or Par-1b -/- 
mice were published in Figure 4.5 of this paper (Lennerz et al., 2010).  I analyzed protein 
lysate from Par-1a or Par-1b null mouse livers and showed that upon short-term 
starvation, Par-1a null mice had increased levels of GS and pGS protein in the liver 
whereas Par-1b null mice do not (Fig. 4.5F).  Since Par-1a null mice demonstrate 
resistance to steatosis (accumulation of lipids, leading to fatty liver) as well as defective 
gluconeogenesis, I probed for UCP2 (an uncoupling protein) in fasted and nonfasted liver 
samples but found similar protein levels (Fig. 4.S1A).  Most recently, autophagy has been 
linked to lipid (Singh et al., 2009) as well as glycogen/glucose homeostasis (Kotoulas et 
al., 2004; Kotoulas et al., 2006). Therefore, I detected LC-3 protein levels by Western 
blot as a marker for membrane formation and early stages of autophagy, but observed no 
differences (Fig. 4.S1B). 
In summary, livers from Par-1a null mice are depleted of lipid and glycogen 
stores, upregulate glycogen synthase, and activate autophagy.  The increase in total 
glycogen synthase protein might be to compensate for the decreased levels of stored 
glycogen.  However, we also observe an increase in the inhibited (phosphorylated) form 
of glycogen synthase (pGS). Thus, it is unclear whether glycogen synthase activity is 
altered in the livers of Par-1a null mice even though an increase in total glycogen 
synthase protein is observed. 
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Abstract  
Par-1 is an evolutionarily conserved protein kinase required for polarity in worms, 
flies, frogs and mammals. The mammalian Par-1 family consists of four members. 
Knockout studies in mice implicate Par-1b/MARK2/EMK in regulating fertility, immune 
homeostasis, learning and memory as well as adiposity, insulin hypersensitivity and 
glucose metabolism. Here we report phenotypes of mice null for a second family member 
(Par-1a/MARK3/C-TAK1), which exhibit increased energy expenditure, reduced 
adiposity with unaltered glucose handling and normal insulin sensitivity. Knockout mice 
were protected against high-fat diet-induced obesity, displayed attenuated weight gain, 
complete resistance to hepatic steatosis and improved glucose handling with decreased 
insulin secretion. Overnight starvation led to complete hepatic glycogen depletion, 
associated hypoketotic hypoglycemia, increased hepatocellular autophagy and increased 
glycogen synthase levels in Par-1a-/-, but not in control or Par-1b-/- mice. Intercrossing of 
Par-1a-/- with Par-1b-/- mice revealed that at least one of the four alleles is necessary for 
embryonic survival. Severity of phenotypes followed a rank-order whereby loss of one 
Par-1b allele in Par-1a-/- mice conveyed milder phenotypes than loss of one Par-1a allele 
in Par-1b-/- mice. Thus, although Par-1a and Par-1b can compensate for one another 
during embryogenesis, their individual disruption gives rise to distinct metabolic 
phenotypes in adult mice.  
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Introduction  
Cellular polarity is a fundamental principle in biology (Banks and Humbert, 2008; 
Geldner, 2009; Lindsey, 2004). The prototypical protein kinase originally identified as a 
regulator of polarity was termed partitioning defective (Par-1) due to early embryonic 
defects in C. elegans (Kemphues et al., 1988). Subsequent studies revealed that Par-1 is 
required for cellular polarity in worms, flies, frogs and mammals (Arimura and Kaibuchi, 
2007; Krummel and Macara, 2006; Lizcano et al., 2004; Martin and St Johnston, 2003; 
Nance, 2005; Shin et al., 2006; Sodha et al., 2002). An integral role for Par-1 kinases in 
multiple signaling pathways has also been established and although not formally 
addressed, multi-functionality for individual Par-1 family members is implied when 
reviewing the list of recognized upstream regulators (Table 4.1A) and downstream 
substrates (Table 4.1B). Interestingly, for many Par-1 substrates the phosphorylated 
residues generate 14-3-3 binding sites (Dalal et al., 1999; Dequiedt et al., 2006; 
Goransson et al., 2006; Kao et al., 2001; Kusakabe and Nishida, 2004; Lin et al., 2009; 
Muller et al., 2001; Muller et al., 2003; Peng et al., 1998; Suzuki et al., 2004; Watkins et 
al., 2008; Zhang et al., 1997). 14-3-3 binding, in turn, modulates both 
nuclear/cytoplasmic as well as cytoplasmic/membrane shuttling of target proteins thus 
allowing Par-1 activity to establish intracellular spatial organization (Bronisz et al., 2006; 
Watkins et al., 2008). Phosphorylation of Par-1 itself promotes 14-3-3 binding thereby 
regulating its subcellular localization (Goransson et al., 2006; Kusakabe and Nishida, 
2004; Watkins et al., 2008). 
The mammalian Par-1 family contains four members (Table 4.2). Physiological 
functions of the Par-1b kinase have been studied using targeted gene knockout 
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approaches in mice (Bessone et al., 1999; Hurov et al., 2001). Two independently derived 
mouse lines null for Par-1b, have implicated this protein kinase in diverse physiological 
processes, including fertility (Bessone et al., 1999), immune system homeostasis (Hurov 
et al., 2001), learning & memory (Segu et al., 2006), positioning of nuclei in pancreatic 
beta cells (Fu et al., 2009; Granot et al., 2009) as well as growth and metabolism (Hurov 
et al., 2007).  
Beyond Par-1b, most information regarding the cell biological functions of the Par-1 
kinases comes from studies on Par-1a. Specifically, Par-1a has been implicated in 
pancreatic- (Parsa, 1988), and hepato-carcinogenesis (Kato et al., 2001), as well as 
colorectal tumors (Parsons et al., 2005), hippocampal function (Wang et al., 2007), CagA 
(Helicobacter pylori) associated epithelial cell polarity disruption (Saadat et al., 2007) 
and Peutz-Jeghers-Syndrome (Jansen et al., 2006), although the later association has 
recently been excluded (Jansen et al., 2006). As a first step towards determining unique 
and redundant functions of Par-1 family members, mice disrupted for a second member 
of the family (Par-1a/MARK3/C-TAK) were generated. We report that Par-1a-/- mice are 
viable and develop normally; adult mice are hypermetabolic, have decreased white and 
brown adipose tissue mass, and unaltered glucose/insulin handling. However, when 
challenged by high-fat diet, Par-1a-/- mice exhibit resistance to hepatic steatosis, 
resistance to glucose intolerance and delayed onset of obesity relative to control 
littermates. Strikingly, overnight starvation results in a complete depletion of glycogen 
and lipid stores along with an increase in autophagic vacuoles in the liver of Par-1a-/- but 
not Par-1b-/- mice. Correspondingly, Par-1a-/- mice develop hypoketotic hypoglycemia. 
These findings reveal unique metabolic functions of two Par-1 family members.  
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Results 
Gene targeting was employed to determine the consequences of Par-1a loss in 
mice (Fig. 4.1A). The targeted Par-1a allele was introduced by electroporation into RW4 
embryonic stem (ES) cells, derived from the mouse strain 129X1/SvJ. Southern blot 
analysis identified correct targeting events (Fig. 4.1B). Southern blotting and PCR 
analysis demonstrated that the agouti offspring produced by the chimeric males were 
heterozygous for the Par-1a locus (data not shown). F1 heterozygous offspring were 
inter-crossed and F2 offspring were genotyped by PCR (Fig. 4.1C). Western blotting 
demonstrated that the targeted disruption of Par-1a produced a null allele of the locus 
(Fig. 4.1D) and multi-tissue Western blotting confirmed ablation of Par-1a/b in all 
tissues of the corresponding null-mice (Fig. 4.1E). 
Higher levels of Par-1a were noted in several tissues of Par-1b null mice 
including brain, BAT, thymus and muscle (Fig. 4.1 E, lanes 2, 5, 17, 26), which may 
provide an explanation for Par-1a compensation of Par-1b loss (see below). However, 
increased Par-1b levels were not observed in Par-1a null tissues. Also observed in Fig. 
4.1E is the differential expression of Par-1a splice variants in various mouse tissues. The 
NCBI database contains 5 Par-1a splice variants with their respective protein products 
ranging from 659 to 753 amino acids. It is not known whether functions differ among the 
various splice variants. 
Par-1a-/--mice are hypermetabolic and show 9% reduction in body weight  
When Par-1a heterozygotes were intercrossed, the offspring contained WT, HET 
and KO pups, although genotype proportions deviated significantly from expected 
Mendelian ratios with loss of homozygous KO mice (n=750; WT=30%, HET=52%, 
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KO=17%; !2=27.864, P<0.0001). All pups developed without any visible dysmorphisms 
or obvious external pathology; and animals survived to adulthood. Par-1a null mice 
exhibited significant weight differences compared with their wild-type littermates (e.g. at 
32 weeks: WT (n=6) 33.4±0.94g; vs. Par-1a-/- (n=6) 25.5±0.42g; P<0.0001, t-test). In 
contrast to Par-1b null mice that show reduced weights at 6 weeks of age (Bessone et al., 
1999; Hurov and Piwnica-Worms, 2007), in Par-1a null mice the difference was not 
discernable this early (Fig. 4.2A, 4.2B). 
Body weight represents a net balance of food intake and energy expenditure. 
Based on the decreased weight in Par-1a null mice we measured total energy expenditure 
(EE), total metabolic rate (MR) and respiratory quotients of male mice on a regular chow 
diet. Par-1a null mice exhibited higher O2 consumption (MR: ~9% increase; Fig. 4.2C) 
and higher EE (10% increase; Fig. 4.2D). We also compared the respiratory quotient 
(RQ=VCO2/VO2) as a measure of fuel-partitioning patterns and RQ ranged from 0.76-
0.78 (Fig. 4.2E; P=0.32, t-test). Food intake in Par-1a null mice was slightly lower than 
WT littermates, although this difference was not statistically significant (WT 3.15±0.09 
vs. Par-1a-/- 2.94±0.04; P=0.16, t-test; Fig. 4.2F). Thus, unlike Par-1b null mice, Par-1a 
null mice are not hyperphagic (Hurov et al., 2007). The lack of effect on RQ suggests that 
there was no difference in fuel selection between carbohydrates and lipids, leading us to 
explore whether the increase in energy expenditure might occur secondarily to increased 
thermogenesis. However, body temperatures of Par-1a null mice were similar to WT 
littermates (WT 34.3±0.5 vs. Par-1a-/- 34.1±0.8; P=0.8, t-test) and expression of 
uncoupling proteins in selected tissues showed no significant difference (Fig. 4.S1). 
Lastly, Par-1a null mice showed similar levels of activity (comparison to WT; P=0.96) 
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and basic sensorimotor testing as well as open field tests showed no significant difference 
(P=0.64; not shown).  
Par-1a-/--mice are normoglycemic, normoinsulinemic and show no insulin sensitivity 
Serum levels of insulin, glucagon, leptin, adiponectin, triglycerides, cholesterol 
and free fatty acids in Par-1a null mice were measured and compared to values from WT 
and Par-1b null mice (20-week-old on regular chow diet; Table 4.3). Male Par-1a null 
mice exhibited 1.6-fold higher levels of adiponectin when compared to WT littermates. 
Par-1b null mice showed a significant decrease in female adiponectin values. In contrast 
to Par-1b null mice, Par-1a null mice showed no difference in serum insulin levels 
(Table 4.3) and blood glucose was normal (WT 152±18mg/dl vs. Par-1a-/- 147±5 mg/dl; 
P=0.216, t-test). Par-1a null mice on CD exhibited ITT curves identical to that of WT 
littermates (Fig. 4.2G; P=0.87; 1-way ANOVA). On CD, Par-1a null mice showed no 
significant difference in GTT relative to WT littermates (Fig. 4.3C) (P=0.15; t-test and 
P=0.181, 2-way ANOVA for entire time course; Par-1b-/- not shown). 
Par-1a-/- mice show delayed weight gain on high-fat diet 
The striking resistance to high fat diet (HFD)-induced weight gain in Par-1b null 
mice (Hurov et al., 2007), prompted us to challenge Par-1a null mice with a similar HFD 
for 16 weeks (Fig. 4.3A, 4.3B). The main finding was reduced weight gain of Par-1a null 
mice compared to WT littermates on HFD (Fig. 4.3A). Specifically, while Par-1b null 
mice on HFD showed statistically significant lack of weight gain after 7 weeks 
[t(7w)=3.297 P<0.05 to t(17w)=7.234; P<0.001, 2 way ANOVA with Bonferroni 
posttests; weight gain: +5%; CD: 19±0.75g vs. HFD: 20.3±1.34, P=0.4097, t-test], Par-
1a null mice on HFD continued to gain weight during the entire experiment (Par-1a-/-: 
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+39%, CD: 23.47±1.6g vs. HFD: 32.4±1.47, P=0.004, t-test), albeit at a reduced rate and 
significantly different from WT littermates (WT: +70%, CD: 27.12±0.5g vs. HFD: 
46±0.9, P=0.001; t-test).  HFD food intake of Par-1a null mice was similar to that of WT 
littermates (P=0.39, t-test). While the Par-1a phenotype with reduced rate of weight gain 
is at first glance less dramatic than that observed in Par-1b null mice [Par-1a-/- vs. WT: 
t(all)=2.779, P<0.05, 1 way ANOVA with Bonferroni’s Multiple Comparison test], it is a 
highly significant finding (Fig. 4.3B, P=0.001). Par-1a null mice required 7 additional 
weeks of HFD to reach the original weight of their WT littermates. 
Par-1a-/--mice show resistance to glucose intolerance on high-fat diet 
Next, Par-1a null mice fed a HFD were subjected to glucose tolerance testing (Fig. 
4.3C). As expected, WT mice on HFD exhibited glucose intolerance relative to WT mice 
on CD with prolonged elevation of blood glucose of ~400% from 15 min onwards 
(t=3.645, P<0.01; 2-way ANOVA). Strikingly, Par-1a null mice exhibited improved 
glucose tolerance on HFD relative to WT-controls on the same diet [Fig. 4.3D; P=0.041, 
t-test (two genotypes); t=3.38; P<0.01; 1-way ANOVA (all genotypes)]. GTT response in 
Par-1a null mice under HFD-conditions was essentially identical to WT and Par-1a null 
mice on CD [Fig. 4.3D; P=0.4781, t-test (two genotypes); t=0.346; P>0.05 1-way 
ANOVA (all genotypes); not shown].  We conclude that Par-1a-disruption leads to 
maintenance of normal glucose tolerance even under HFD-conditions; accordingly Par-
1a null mice on HFD were normoglycemic (P=0.3, t-test).  Next, we examined serum 
insulin levels in HFD-fed mice during the first 60 min of the GTT (Fig. 4.3D) and found 
significantly lower levels in Par-1a null mice (t=3.16, P=0.0194, t-test (two genotypes); 
F=6.454, P=0.018, 1-way ANOVA). Although we did not formally assess insulin 
 -118- 
tolerance in Par-1a null mice on HFD, the combination of improved glucose tolerance 
and reduced insulin secretion during the GTT is indicative of peripheral insulin 
hypersensitivity. Thus, Par-1a null mice demonstrate normal insulin and glucose 
sensitivity, unless challenged by HFD. In contrast Par-1b null mice exhibited insulin 
hypersensitivity even on a CD (Hurov et al., 2007). Direct assessment of pancreatic islets 
has proven difficult in Par-1 mice (Granot et al., 2009), however, morphological and 
morphometric differences were not observed in the islet organ of Par-1a null mice (not 
shown).  
Par-1a-/--mice show diet-dependent reduced adiposity  
Next, we determined whether the reduced body weight of Par-1a null mice was 
reflected disproportionately in different tissues (Fig. 4.4A). Measurements of tissue 
weights in Par-1a null mice indicated that decreased weights of most organs were 
proportional to total body weight and consistent with a decrease in overall body mass, 
rather than in specific organs. However, two tissues did not follow this rule and were 
disproportionately smaller: white-adipose tissue (WAT from gonadal fat pads) and 
brown-adipose tissue (BAT).  We also performed dissection of tissues in the mice on 
HFD and, as expected, the energy excess in WT-mice led to a disproportionate increase 
in overall adiposity (Fig. 4.4A; BAT-CD vs. BAT-HFD P=0.001; WAT-CD vs. WAT-
HFD P=2.5e-5; t-tests). Par-1a null mice showed a similar disproportionate increase in 
overall adiposity (BAT-CD vs. BAT-HFD P=0.007; WAT-CD vs. WAT-HFD P=1.4e-9; 
t-tests) with a weight increase in BAT and gonadal WAT that eliminated the reduced 
adiposity observed under chow diet (Fig. 4.4A columns a vs. b and c vs. d, both P=0.08; 
t-tests).  
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Dissection of the gonadal fat pads (Fig. 4.4B), representative of the WAT showed 
a disproportionate decrease in fat mass of Par-1a null mice relative to WT on CD (Fig. 
4.4C; raw weight values provided). The weight difference corresponds to ~48% (Par-1a-/-
) and ~36% (Par-1b-/-) of the WT-WAT weight, respectively (Fig. 4.4C). Although we 
did not quantitatively assess abdominal fat, during dissection the dimensions of 
mesenteric root, omental-, and retroperitoneal fat content were strikingly lower in Par-1a 
null mice and this difference is not accounted for in the displayed values of gonadal 
WAT (Fig. 4.4C). 
Dissection of the interscapular fat depot, representative of BAT, is shown in Fig. 
4.4E. The weight difference corresponds to ~52% (Par-1a-/-) and ~38% (Par-1b-/-) of the 
WT-BAT weight, respectively (Fig. 4.4F). For both adipose tissues, the difference 
significantly exceeded the overall ~9% weight difference observed in Par-1a null mice. 
Adipocyte counts from six independent samples of WAT and BAT indicated no 
differences in adipocyte size from WT and Par-1a null mice: WAT (WT 436±100 
adipocytes per mm2 vs. Par-1a-/- 419±74; P=0.137, t-test) and BAT (WT 1894±349 vs. 
Par-1a-/- 1385±434; P=0.382, t-test). Thus, we conclude that the observed decrease in 
adipose tissue of Par-1a null mice is due to decreases in total adipocyte cell number, not 
cell size; findings similar to those made in Par-1b null mice (Hurov et al., 2007). 
We also determined the weight of muscle samples (tibialis anterior, 
gastrocnemius, plantaris, diaphragm, extensor digitorum longus), typically used for 
assessment of myogenic phenotypes and fiber-type composition (Corbett et al., 2001; 
Sanoudou et al., 2006), which, under HFD conditions showed significantly decreased 
weights (Fig. 4.4A, subheading e; WT: P=3.7e-6; Par-1-/-: P=0.006, both t-tests). Skeletal 
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muscle plays an integral role in the coordination of fuel homeostasis (Hegarty et al., 
2009) and is the most important site of insulin-stimulated glucose disposal (DeFronzo et 
al., 1981). We therefore performed functional- (motor, biodistribution and microPET 
analysis), biochemical- (glycogen quantification) and morphologic- (routine, PAS, fiber-
type analysis and ultrastructure) screening of skeletal muscle but observed no differences 
between wild-type and Par-1a null mice (not shown). Thus, the reduced body weight of 
Par-1a mice on HFD is likely accounted for by a combination of reduced muscle mass 
(Argiles et al., 2007; Sitnick et al., 2009) and reduced adiposity; although the latter is not 
reflected in the gonadal WAT measurements (Fig. 4.4Ac,d).  
Par-1a loss causes decreased WAT glucose uptake in the absence of BAT-phenotype 
MicroPET imaging of WAT was performed (not shown); however the reduced 
size of Par-1 null mice and high tracer concentrations in kidneys, bladder and skeletal 
muscle precluded meaningful quantification of uptake in retroperitoneal, gonadal, and 
calf-fat deposits, respectively. We therefore applied invasive biodistribution analysis and 
in contrast to Par-1b null mice, WAT of Par-1a null mice showed significantly decreased 
glucose uptake under normal dietary conditions [Fig. 4.4D; WT: 0.52±0.08%ID/g (n=9) 
vs. Par-1a-/-: 0.32±0.05%ID/g (n=8); U=14, P=0.036, Mann-Whitney U test; P=0.05, t-
test]. When challenged with HFD, Par-1a null mice showed a statistically significant 
increase in 18F-FDG-uptake compared to Par-1a null mice on chow diet that eliminated 
the difference of glucose uptake in comparison to WT on HFD (Fig. 4.4D).  
We next examined glucose uptake in BAT of chow fed Par-1a null mice by 
microPET analyses of the interscapular BAT (Fig. 4.4G). We evaluated 4 different 
conditions at 1h post 18F-FDG injection: the fed and fasted state using acute insulin 
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challenge vs. saline. As part of the HFD-trial, we also examined BAT glucose uptake via 
biodistribution analysis in all genotypes. We found that loss of Par-1a did not 
significantly alter BAT glucose uptake in any of these 6 tested conditions (not shown).  
Although Par-1a null mice exhibited reduced fat mass on chow diet, and delayed 
weight gain relative to WT on HFD, sampled gonadal adipose mass in Par-1a null mice 
was not significantly different compared to WT after 16 weeks of HFD conditions [Fig. 
4.4C, F; P=0.12/P=0.13, both t-tests; WAT/BAT; n=8 Par-1a-/- vs. n=17 WT]. In contrast, 
the BAT/WAT mass in Par-1b null mice remained reduced under HFD conditions when 
compared to WT-mice on the same diet [Fig. 4.4C, F; P=0.002/P=0.04, t-tests 
(WAT/BAT); n=6 Par-1b-/- vs. 17 WT]. 
Par-1a-/--mice show resistance to hepatic steatosis 
Chronic exposure of mice to HFD causes liver injury via accumulation of lipids, 
leading to fatty liver (steatosis) (Bradbury, 2006; Postic et al., 1999). The absence of 
steatosis in Par-1a null mice was apparent from gross examination of the liver, which 
was notably darker than that of the WT littermates (not shown) and histologic 
examination that showed abundant panlobular, macrovesicular steatosis in WT (Fig. 
4.5Ab, inset) but not Par-1a null livers (Fig. 4.5Ad). Remarkably, with respect to hepatic 
steatosis, Par-1a null mice on HFD were no different than WT mice on CD (compare Fig. 
4.5Ad with 4.5Aa). Based on previous findings (Hurov et al., 2007), we quantified 
hepatic lipid content in fresh-frozen sections stained with Oil-red O and found 14.6-25% 
in WT vs. 6.4-7.7% in Par-1a null mice, when expressed as percent fat per high-power 
field (Fig. 4.5B). The quantitative difference in the WT on chow diet (Fig. 4.5B) 
corresponds to an absence of centrilobular (Zone III) lipid accentuation in Par-1a null 
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mice (compare WT Fig. 4.5Aa to Fig. 4.5Ac). In addition, biodistribution studies 
demonstrated identical 18F-FDG-uptake in livers of Par-1a null- and WT-mice on chow 
standard CD and HFD (not shown). Similarly, microPET examination of the liver using 
four different metabolic conditions (see methods) did not show significant differences (P-
value range: 0.12-0.71, t-tests). These findings indicate that Par-1a null mice show 
resistance to steatosis in the absence of altered hepatic glucose uptake under both normal 
and HFD-conditions. 
Decreased glycogen deposition in Par-1a-/--livers leads to hypoketotic hypoglycemia 
Storage and utilization of glucose is one of the main contributors to the 
pathophysiologic changes in diabetes (Cline et al., 1994; Shulman et al., 1990). Periodic 
acid Schiff (PAS) staining was used to detect glycogen content (Fig. 4.5C). Fasted WT 
liver showed partially depleted liver glycogen stores (Fig. 4.5Ca), whereas liver sections 
from fasted Par-1a null mice exhibited complete depletion of hepatic glycogen content 
(Fig. 4.5Cc; PAS-quantification (fasted): WT 23.6±8.5 vs. Par-1a-/- 0.17±0.13, P=0.01, t-
test). This depletion was not observed in Par-1b null mice (Fig. 4.5Ce; Par-1b-/- 
26.68±2.8, P=0.73, t-test). Two hours after glucose administration, glycogen levels were 
substantially elevated and visible as confluent PAS-positive in livers of WT mice (Fig. 
4.5Cb). In contrast Par-1a null mice showed absence of restoration of hepatic glycogen 
content with only spotty PAS-positive islands (Fig. 4.5Cd). Quantitative enzymatic 
analysis of glycogen was consistent with the PAS staining such that fasted and glucose-
stimulated liver glycogen was significantly decreased in Par-1a null animals (Fig. 4.5D) 
with no significant difference in Par-1b null mice.  After feeding glycogen levels were 
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normal and no significant histological differences were observed between groups (not 
shown).  
To test the physiologic significance of hepatic glycogen depletion in Par-1a null 
mice we performed an extended fasting experiment and observed significantly decreased 
glucose levels in Par-1a null mice after overnight fasting (20 h) when compared to WT 
littermates (Fig. 4.5E). After 4 additional hours without external energy sources, Par-1a 
null animals blood glucose levels further declined (P=0.04 in comparison to WT, t-test) 
and the mice developed hypoketotic hypoglycemia (Fig. 4.5E). In contrast, Par-1b null 
mice showed an absence of physiologic decline of blood glucose levels with 
appropriately low ketone levels (Fig. 4.5E).  
To test whether the tissue differences in glycogen levels relate to glycogen 
synthesis we determined total and phospho-glycogen synthase (GS) levels (pGS; Fig. 
4.5F) and found increased levels of GS and pGS in the livers of Par-1a null mice. Since 
Par-1a null mice demonstrate resistance to steatosis as well as defective gluconeogensis 
we probed for UCP2 in fasted and non-fasted liver samples but found similar protein 
levels (Fig 4.S1). Most recently autophagy has been linked to lipid (Singh et al.) as well 
as glycogen/glucose homeostasis (Kotoulas et al., 2004; Kotoulas et al., 2006). Therefore, 
we monitored LC-3 as a marker for membrane formation and early stages of autophagy 
but observed no differences (Fig. 4.S1). Electron microscopic examination of livers from 
fasted WT mice demonstrated irregularly shaped glycogen islands (Fig. 4.5Ga, 4.5Gb) 
and variably sized lipid vacuoles (Fig. 4.5Gb) in close proximity to mitochondria with 
normal morphology (Fig. 4.5Gc). In striking contrast, livers from fasted Par-1a null mice 
did not have lipid vacuoles (Fig. 4.5Gd, 4.5Ge) were completely depleted for glycogen 
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(Fig. 4.5Gd, 4.5Ge) and had abundant autophagocytic vacuoles throughout the 
hepatocytes (Fig. 4.5Ge, 4.5Gf). These autophagic vacuoles were normally configured 
and frequently associated with mitochondria (Fig. 4.5Gf). Our ultrastructural findings 
with WT mice indicate a catabolic state whereas the findings in Par-1a null liver are 
indicative of more extreme energy deprivation with self-digestion of organelles (Fig. 
4.5Gf). 
Par-1b/Par-1a-double mutants are not viable and at least one allele is necessary for 
embryonic survival 
Next, crossbreeding experiments were performed to obtain mice disrupted for 
both Par-1a and Par-1b. After an initial experiment where 24 intercrosses were 
performed and only 6 of the 9 possible genotypes were obtained, genotype frequencies in 
ongoing HH x HH crosses were monitored. Eventually 2 of the 3 missing genotypes were 
obtained (Fig. 4.6A) but at a substantial deviation from the expected Mendelian ratio 
[Chi-squared (8)>944= 2.18e-198] and with a complete absence of mice lacking both Par-
1a and Par-1b (KK). In addition, there was a drastic reduction in numbers of KH and HK 
mice (0.5% and 2.7%, respectively).  Instead of the expected 12.5% (corresponding to an 
estimated n of 308 mice; grey background in Fig. 4.6A), we obtained a total of 14 KH 
and 69 HK mice (out of n=2466). Next, pregnant females that had been superovulated 
from HH intercrosses were sacrificed and fetuses at day 10.5 (n=4) or day 8.5 (n=4); post 
coitum were isolated. None of the obtained sets of embryos (total n=31) included the KK 
genotype (expected frequency: ~2 mice). All other genotypes were obtained (not shown). 
These results illustrate Par-1b/Par-1a double mutants are not viable and that at least one 
allele of either Par-1a or Par-1b is necessary for viability and likely embryonic survival.  
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When normalized to age-matched WT-controls, Par-1b null mice are ~20% 
reduced in body weight (Hurov et al., 2007) and Par-1a null mice are ~9% reduced in 
body weight (this study). Loss of one Par-1a allele in Par-1b null mice (KH) led to a 
more pronounced reduction in body weight (30%) than that observed in Par-1a null mice 
containing a single allele of Par-1b (HK, 23%; Fig. 4.6B). HK and KH mice were not 
healthy and a high proportion of these animals died shortly after birth (not shown). The 
severity of phenotypes observed in each genotype followed the order: 
KK>KH>HK>KW>WK>WW and suggests an intriguing gene-dosage effect at the 
organism level.  
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Discussion  
This study describes metabolic phenotypes arising in mice disrupted for Par-1a 
and the consequences of intercrossing of Par-1a with Par-1b deficient mice. Par-1a null 
mice are hypermetabolic, show reduced body weight, decreased adiposity, resistance to 
hepatic steatosis and hypofertility; features reminiscent of the Par-1b null phenotype 
(Hurov et al., 2007).  Metabolic phenotypes of Par-1a null mice not shared by Par-1b 
null mice include 1) hepatic glycogen depletion after starvation associated with 
hypoketotic hypoglycemia and increased autophagic vacuoles in the liver; and 2) a 
modestly reduced glucose uptake by WAT when mice were fed a standard chow diet. 
Features observed in Par-1b null mice but not in Par-1a mice include 1) hyperphagy 
(food intake of Par-1a null mice was equivalent to controls); 2) reduced serum insulin 
levels under both fed and fasting conditions on a standard CD (serum insulin levels in 
Par-1a null mice were lower than those measured in WT littermates fed a HFD but not 
standard CD); 3) increased insulin sensitivity on standard CD (Par-1a null mice were 
insulin sensitive on a HFD but not standard CD); 4) resistance to HFD-induced weight 
gain (Par-1a null mice showed a reduced rate of weight gain relative to control 
littermates when fed a HFD); 5) enhanced glucose uptake in BAT (loss of Par-1a did not 
affect glucose uptake in BAT under any condition); and 6) resistance to hepatic steatosis 
accompanied by enhanced glucose uptake in liver (Par-1a null mice, resistance to hepatic 
steatosis was not accompanied by enhanced hepatic glucose uptake).  
  Strikingly, Par-1a null mice on HFD exhibited profound resistance to the 
development of glucose intolerance (Fig. 4.3D) as well as delayed weight gain on HFD 
(Fig. 4.2A). These findings are most likely related to peripheral insulin hypersensitivity 
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as illustrated by resistance to glucose intolerance and decreased insulin secretion during 
GTT (on HFD). Par-1a null livers maintained resistance to steatosis despite HFD 
challenge (Fig. 4.5A, 5B).  However, the adiposity and WAT glucose uptake measured in 
Par-1a null mice fed a HFD were similar to those of WT littermates fed the same diet. 
Although this study does not provide conclusive evidence for a hepatocyte-autonomous 
role for either Par-1a or Par-1b in lipogenesis, the striking resistance to hepatic steatosis 
seen in both models may suggest such a function. 
Upon short-term starvation, the livers of Par-1a null mice exhibited profound 
defects in both glycogen storage and glucose mobilization (gluconeogenesis), phenotypes 
not observed in Par-1b null mice. Depletion of both lipid and glycogen stores, 
upregulation of glycogen synthase as well as activation of autophagy are observed in the 
livers of Par-1a null mice. The increase in total glycogen synthase might be a 
compensatory response in light of the decreased glycogen storage. However, we also 
observe an increase in the inhibited (phosphorylated form) of glycogen synthase.  Thus, it 
is unclear whether the net glycogen synthase activity is altered in the livers of Par-1a-/- 
mice. Our ultrastructural findings of increased autophagy in the absence of glycogen or 
lipid vacuoles in the livers of Par-1a null mice, suggests substantial energy deprivation 
with self-digestion of organelles. The absence of both hepatic glycogen mobilization and 
gluconeogenesis required to maintain normal blood glucose levels during starvation, in 
turn, leads to hypoglycemia and hypoketosis in Par-1a null mice.  
The underlying molecular mechanisms driving the hypermetabolic phenotype and 
resistance to hepatic steatosis in Par-1a null mice and the inability of these mice to 
maintain metabolic homeostasis during periods of starvation remain unclear. The 
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regulation of lipogenesis, glucose metabolism and autophagy are coordinated, at least in 
part, through the Par-1 related kinase AMPK. It is tempting to speculate that Par-1 may 
regulate these pathways via a common mechanism. To test this, we monitored the 
activation state of the mTOR pathway by assessing levels of phospho- and total AKT, 
phospho- and total AMPK, phospho- and total p70S6K, phospho- and total pS6 
ribosomal protein, and LC3 in the livers of Par-1 deficient mice during starvation and 
upon re-feeding. We did not observe any consistent alterations in the levels or activation 
state of these proteins. Curiously, although both AMPK and SIK kinases negatively 
regulate lipogenesis via SREBP1c, the phenotypes of Par-1 null mice suggests Par-1 is a 
positive regulator for lipogenesis in adipocytes and hepatocytes. The molecular 
mechanism underlying the phenotypes of Par-1a null mice will require tissue specific 
deletion and identification of specific downstream targets of Par-1a mediating these 
effects. 
Another major finding of this study is that Par-1b compensates more effectively 
for loss of Par-1a than the reverse and that embryonic survival requires the presence of at 
least one allele of Par-1a/b. Moreover, the presence of only one Par-1a allele in the 
complete absence of Par-1b conveys the most severe phenotype (growth restriction); 
supporting the notion of ranked redundancy with the most severe phenotype observed in 
the very rare KH (Par-1b-/-/Par-1a+/-) mutant.  
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Materials and Methods 
 Animal Procedures. The Washington University School of Medicine Animal 
Studies Committee approved all animal procedures. Unless stated otherwise, animals 
were fed a standard chow diet (Purina Mills, St. Louis, MO, Lab Diet 5063 containing 
4.5% fat, 55% carbohydrate, 20% protein and 4.7% fiber) and were housed with free 
access to food and water under a 12h light/dark cycle.  Unless indicated, only male mice 
were analyzed throughout this study. 
Construction of the Par-1a targeting construct. A Par-1a genomic clone was 
isolated from a 129X1/SvJ mouse embryonic (ES) cell genomic library by hybridization 
with an isogenic 0.9 kb Par-1a-specific cDNA probe. The genomic organization of the 
mouse Par-1a gene was disrupted by replacing a 1.9 kb Sac I/Hpa I fragment with a 1.2 
kb neomycin phosphotransferase cassette (Fig. 4.1A). The replacement disrupts exon 2 
encoding the ATP binding domain of Par-1a and also destroys the 5’ splice site between 
introns 2 and 3.  The insertion of the neomycin selection cassette alters the Pst I fragment 
from a single 13.8 kb fragment to two fragments of 7.5 and 5.9 kb, and this change was 
used to identify targeted ES cell clones and knockout animals by Southern blotting (Fig. 
4.1B) using the 5’ and 3’probes indicated in Fig. 4.1A. Using mouse genomic DNA as 
template, the 425 bp 5’-probe was amplified by PCR with primers of 5’-
TGGTGGTACACGCCTGTATTC and 5’-CTGATCTACACAATTCCAGGAC. The 204 
bp of 3’-probe was amplified by PCR with primers of 5’-
GCATCTTGGGCTGTAAGTGATG and 5’-GGCTTACAACCATCTGTACAG.  
PCR analysis. PCR of tail DNA/tissues was achieved using a three-primer PCR 
reaction with one 5’ primer from exon 2 (5'-GGAGACGGGAGGCAAGAAGTCA), a 3’ 
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primer from the intronic sequence between exons 2 and 3 (5'-
GGCTCATTCCCTTGGTGTACTT), and a 3’ primer from the neomycin cassette 
(5'GAGCAGCCGATTGTCTGTTGT), resulting in 400 bp (KO) or 300 bp (WT) bands, 
respectively (Fig. 4.1C). 
 Generation of mice harboring the Par-1a mutation. RW4 ES cells were 
electroporated with linearized targeting vector and selected with Geneticin (G418; 
Invitrogen) using established protocols developed in the Murine Embryonic Stem Cell 
Core of the Alvin J. Siteman Cancer Center at Washington University School of 
Medicine and Barnes-Jewish Hospital; details available online http://escore.im.wustl.edu. 
A total of 96 G418-resistant ES cell clones were analyzed for homologous recombination 
by Southern blotting and 3 clones were found to be positive. Positive ES clones were 
karyotyped and microinjected into 3.5 dpc C57BL/6 blastocysts, which were 
subsequently implanted into the uteri of pseudopregnant C57BL/6 X C3HF1 foster 
mothers. Male chimeras selected by percentage of agouti color were mated to C57BL/6 
females. Germ line transmission was determined by agouti coat color. F1 animals were 
tested for the targeted Par-1a allele by Southern blotting and PCR analysis of tail DNA. 
Heterozygous F1 males/females were interbred to generate F2 littermates used for 
subsequent breeding and analysis; referred to as wild type (WT), heterozygotes (HET) 
and null (KO) pups/mice. 
Western blotting.  Tissues from wild-type (WT) and knock-out animals were 
homogenized in 800 µl of mammalian cell lysis buffer (MCLB: 50 mM Tris-HCl pH 8.0, 
5 mM EDTA, 0.1 M NaCl, 0.5% NP40, 2 mM DTT) containing 1 µM microcystin, 1 mM 
sodium orthovanadate, 10 mM !-glycerol phosphate, 1 mM sodium fluoride, 2µM PMSF, 
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plus protease- (Sigma, St. Louis, MO) and phosphatase-inhibitor cocktails (Calbiochem, 
Gibbstown, NJ).  Homogenates were rocked for 15 min at 4oC and then clarified twice by 
centrifugation. Clarified lysates were resolved by SDS-PAGE on a 10% SDS gel 
followed by Western blotting was carried out with antibodies specific to actin (1:4,000, 
Sigma Chemical Co.), tubulin (Sigma, 1:1000), !-catenin (1:10,000, BD 
Biosciences/Pharmagen) and Par-1a ascites (1:10,000) (Hurov et al., 2004), Glycogen 
Synthase (1:1000; Cell Signaling), phospho-Glycogen Synthase (1:1000; Cell Signaling) 
and LC-3 (1:1000; Cell Signaling).  Par-1b was detected with ascites generated using a 
monoclonal antibody produced against KLH-conjugated peptide corresponding to amino 
acids 288-307 (PDYKDPRRTELMVSMGYTRE) of human Par-1b.  Bound primary 
antibodies were detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse 
antibody (Jackson, West Grove, PA) and proteins were visualized by chemiluminescence.   
Tissue distribution.  Distribution of Par-1a and Par-1b in various tissues was 
examined using a modified Western blot protocol. In brief, mouse tissues harvested from 
~6-month-old mice were homogenizing in 0.8 ml of Mammalian Cell Lysis Buffer (see 
above). Lysates were rocked for 15 min at 4oC followed by centrifugation for 10 min at 
20,800g. Clarified supernatants were transferred to pre-chilled tubes. Proteins were 
resolved by SDS-PAGE on 7.5% gels until the 50 kDa molecular weight marker was at 
the bottom of the gel. Proteins were transferred to nitrocellulose membranes in CAPS 
buffer (Sigma C2632, St. Louis, MO) 0.1M 3-(cyclohexylamino)-1-propanesulfonic acid 
and 10% methanol at 1.2 mA for 1.5 h.  Membranes were blocked in 1xTBST (100 mM 
Tris pH 8.0, 1.5 M Sodium Chloride, 2% Tween-20) containing 5% milk for 1h. 
Membranes were probed with Par-1a ascites (1:10,000), Par-1b ascites (1:1,000), actin 
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(1:4,000, Sigma Chemical Co.), or !-catenin antibody (1:30,000) by rocking overnight at 
4oC. Membranes were washed 4 times for 13 min each in 1x TBST. Membranes were 
then incubated with a goat anti-mouse antibody (dilution 1:30,000; Jackson West Grove, 
PA) for 1 h at room temperature. Membranes were then washed 4 times in 1x TBST for 
13 min each.  Blots were developed using ECL detection reagent (GE Healthcare, 
Piscataway, NJ). 
Breeding, animal weights and growth measurements. Embryos and pups 
generated from heterozygous crosses were weighed and genotyped by PCR analysis. Plug 
observation was recorded as 0.5 days post coitis (dpc); embryos were harvested, rinsed 
and weighed. Mean body weights at each time point were compiled from at least 6 mice 
per genotype. Breeding schemes followed standard protocols and for double-knock-out 
(DKO) experiments genotypes are abbreviated by a two-letter code (first letter: Par-1b; 
second letter: Par-1a; W=+/+; H=+/-; K=-/-; e.g. HK). Binning and comparison within and 
between genotypes via uni- and multivariate analysis tested trends over time. We 
assessed number and genotype of litters in 10 superovulated timed pregnancies at 8.5 dpc 
and 10.5 dpc. Offspring ratios for Par-1a-/-, Par-1b-/- as well as all genotypes in DKO-
experiments were recorded as pups/litter and total number per genotype. Significance of 
deviations from expected Mendelian ratios were tested using Chi-square statistics with 2-
degrees (WT, HET, KO) or 8-degrees of freedom (KK, WW, WK, KW, WH, HW, KH, 
HK, HH) in Par-1a null and DKO experiments, respectively (two-tailed P values are 
provide). 
Metabolic measurements (indirect calorimetry). Metabolic measurements 
followed previously established protocols (Bernal-Mizrachi et al., 2002; Hurov et al., 
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2007). Briefly, metabolic characterization included metabolic rate, energy expenditure, 
activity, food consumption (in g/day), and body temperature. During data analysis, 
energy expenditure and metabolic rate were normalized with respect to body weight. 
Energy expenditure and respiratory quotient (RQ) were calculated from the gas exchange 
data: RQ as the ratio of VCO2 to VO2, Heat = (3.815 + 1.232 * RQ) * VO2. Activity was 
measured on an x- and z-axis using infrared photobeams to count the amount of beam 
breaks. 
High-fat diet (HFD) studies. HFD studies followed previously published 
protocols (Hurov et al., 2007) and consisted of a total of 55 mice. In thirty-five 3-week-
old mice (WT, Par-1a-/-, Par-1a-/-) the regular rodent chow diet (CD) was replaced with 
Adjusted Calories Diet (42% fat) from Harlan Teklad (88137 ‘Western’ diet; Madison, 
WI). The weight of the HFD chow was recorded and food consumption as well as mouse 
weight was determined for individual mice on a weekly basis. Although resistance to 
weight gain on HFD has been previously reported for Par-1b null mice (Hurov et al., 
2007), for direct comparison and determination of specific organ uptake values, the HFD 
experiment included a new group of 9 Par-1b null mice and therefore consisted of six 
different trial-groups: WT-CD, WT-HFD, Par-1a-/--CD, Par-1a-/--HFD, Par-1b-/--CD, Par-
1b-/--HFD. Metabolic profiling after a total diet time of 16 weeks consisted of a) fasting- 
(n=18CD, 35HFD) and fed blood glucose levels (n=6 per genotype, randomly selected); 
b) glucose tolerance testing (GTT) on 18 CD-mice (6 per genotype, randomly selected) 
and all HFD-mice; c) 18F-FDG-biodistribution experiments (n=19CD, 31HFD), d) organ 
weights and e) histologic examination. The HFD-trial was designed to allow at least 24h 
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between GTT and 18F-FDG-biodistribution studies, during which animals were kept on 
HFD. 
Serum Factor Quantification.  Serum levels of insulin, triglycerides, 
adiponectin, leptin, and cholesterol were determined by Ani Lytics Incorporated 
(Gaithersburg, MD; n!11 animals per genotype and sex); glucagon and free fatty acids 
were determined according to previously established protocols (Chakravarthy et al., 
2005). 
Glucose and insulin measurements and tolerance tests.  Randomly fed or 
fasted mice were analyzed and blood glucose levels were determined using a "-glucose 
photometer and "-glucose cuvettes (HemoCue AB, Angelholm, Sweden) or Accucheck 
Advantage glucometer (Roche Diagnostics Corp., Indianapolis, IN). Normoglycemia was 
defined as blood glucose values between 90-130 mg/dl. Intraperitoneal (i.p.) glucose 
tolerance tests (GTT) were performed on fasted (12 h) animals on CD and all HFD-trial 
mice. Mice were injected i.p. with D-glucose (20% solution; 1 g/kg of body weight) and 
blood glucose levels were determined at 15, 30, 60, 90 120 min and >24h post injection. 
In addition, insulin levels were determined during GTT immediately before, at 15, 30 and 
60 min after glucose injection. Therefore, ~20-30 µl of blood were collected using the 
Microvette 200 capillary blood collection system (Sarstedt, Newton, NC) and centrifuged 
at 30,000 g for 5 min. Fasting serum insulin levels were determined for 50 male mice on 
CD (n=24WT, 8Par-1a-/-, 18Par-1b-/-) and 18 randomly selected mice on HFD (n=6 per 
genotype) using rat insulin as a standard and ELISA as specified by manufacturer 
(Crystal Chem, Inc, IL). Insulin tolerance tests (ITT) were performed on 6-h-fasted male 
mice (n=9Par-1a+/+, 9Par-1a-/-). Insulin sensitivity in Par-1b null mice has been reported 
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(Hurov et al., 2007) and was not repeated. Blood glucose values were measured 
immediately before and at 15 min intervals for a total of 90 min after i.p. injection of 
insulin (0.30 IU/kg HumulinR, Eli Lilly and Company, Indianapolis, USA). 
MicroPET studies. MicroPET studies entailed imaging of cohorts of male WT 
and Par-1a null mice that were repetitively imaged once a week for four consecutive 
weeks, each time under a different metabolic condition. Brown adipose tissue (BAT), 
skeletal muscle (SM), heart, liver and brain were examined under the following 4 
conditions: mice were either fasted overnight or allowed access to CD (non-fasted). The 
next morning, either 0.5 unit/kg insulin (Humulin N; Eli Lilly, Indianapolis, IN) or saline 
was administered to mice by i.p. injection. Thirty minutes after the injection, mice were 
lightly anesthetized with isoflurane followed by a tail vein injection of 18F-FDG (~200-
500 µCi in saline). Immediately after injection of radiotracer, mice were placed supine in 
the microPET scanner (Focus120 or 220 scanner, Concorde MicroSystems, Knoxville, 
TN) and imaged (acquisition time: ~10 min; 1 bed position; OSEM reconstruction). Mice 
were allowed to recover, then anesthetized and imaged again at 1 h and 2 h post injection 
of radiotracer. The Par-1b null and WT mice used for comparison were age matched 
males and treated as above except that they were imaged on a R4 scanner (Hurov et al., 
2007). MicroPET images were corrected for decay, but not attenuation or scatter, then 
stacked regions-of-interest (ROI) of relevant tissues and organs were analyzed with 
AnalyzePC 6.0 software. ROI counts were converted to counts per gram of tissue (nCi/g), 
assuming a tissue density of 1 g/ml. Data for accumulation of 18F-FDG on microPET 
images were expressed as standard uptake values (SUV), representing counts per gram of 
tissue divided by injected dose of radioactivity per gram of animal weight (Sharma et al., 
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2002; Sharma et al., 2005). After statistical analysis using a one-way ANOVA and 
Student’s t-tests, comparison between genotypes and experiments was enabled by 
normalization of the SUV to the corresponding WT littermates, data for Par-1a and Par-
1b disrupted mice against their littermate WT as normalized average SUV ± SEM; errors 
were propagated (see below). 
18F-FDG biodistribution experiments. As previously reported, white adipose 
tissue (WAT) cannot be analyzed by noninvasive microPET imaging (Hurov et al., 2007). 
As an alternative we examined glucose-uptake of WAT and other organs by traditional 
18F-FDG biodistribution (Bigott et al., 2005; Cirrito et al., 2005; Kesarwala et al., 2006; 
Sharma et al., 2005). Mice were anesthetized with isoflurane (2% vaporized in oxygen), 
followed by tail vein injection of 18F-FDG (20 µCi in 100 µl saline). Sixty minutes after 
18F-FDG injections, mice were sacrificed by cervical dislocation (under anesthesia). 
Blood, liver, heart, brain, muscle, WAT and BAT were rapidly removed, weighed and 
their radioactivity was measured using a Beckman 8000 gamma counter. The percent-
injected dose per gram of tissue (% ID/g) was calculated [(tissue µCi) (injected Ci)-1 (g 
tissue)-1 x 100] and subsequently compared among tissues, genotypes and diets. 
Biodistribution analysis was performed on 31 HFD-mice (17WT; 8Par-1a-/-; 6Par-1b-/-) 
and 19 mice from the CD-arm (age-matched control group; total n=50). Tissue samples 
from these mice were fresh-frozen and stored at -80oC. Subsequent cryostat sections 
confirmed tissues, and allowed histomorphological/ histochemical comparison with 
tissues obtained from animals that did not undergo 18F-FDG uptake (n=5; no differences 
observed) or HFD (see results). For these HFD-trial biodistribution experiments, the 50 
mice were prospectively assigned to one of 9 experimental days with an average of 6 
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animals per experiment (range: 3-10 mice/day). Excluding the 16 weeks on HFD (see 
above), these experiments were performed over a 10-month-period. 
 Starvation experiments. Starvation experiments consisted of determination of 
blood glucose as well as ketone levels using a MediSense Precision Xtra Diabetes 
Glucose and Ketone Monitor System (Abbott, Alameda, CA). After overnight fasting (20 
h) measurements were repeated; one group of mice was subjected to extended fasting 
(additional four hours) and the other group of mice was given an i.p. injection of 2 mg/g 
glucose for 2 h.  Tissues were collected at all time points and samples separated for 
western blotting, routine histology, electron microscopy and glycogen determination. 
Dissection and Histology. Organs were excised, weighed, rinsed in PBS; fixed in 
10% neutral-buffered formalin, rinsed in PBS, and stored in 70% ethanol. Formalin fixed 
tissues were paraffin embedded (FFPE) and sectioned at (~5 !m) using standard 
procedures. For morphologic evaluation and fat content H&E and Oil-red-O staining was 
performed on FFPE and fresh-frozen sections (stored at -80oC), respectively. 
Morphological analysis was performed using multiple independent samples per site/organ 
(13-26 samples per genotype) as well as all 55 animals on the HFD-trial. We quantified 
BAT and WAT samples taken from the interscapular and gonadal fat pads, respectively. 
Quantification was performed using digital image processing via ImageJ (v. 1.37v 
http://rsb.info.nih.gov/ij/) and Photoshop CS3 (Adobe Systems) according to previously 
established semi-automatic protocols (Brunt et al., 1999; Gustot et al., 2006). Specifically, 
Oil-red-O positivity was quantified on >20 high-power fields, cell number or lipid 
vacuoles were quantified on 6-20 randomly chosen images per sample and PAS-staining 
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was quantified using integrated density measurements (IntDen: equivalent to the product 
of area and mean grey value). 
Glycogen determination. Fifty milligrams of liver and skeletal muscle samples 
were extracted with 0.9 N perchloric acid and 99% ethanol to precipitate glycogen. The 
glycogen from the pellet was dialysed, and digested to free glucose with 
amyloglucosidase. Glucose concentrations were measured by the glucose oxidase method 
(Glucose Analyzer II; Beckman Instruments, Fullerton, CA). 
Electron microscopy (EM). EM was performed according to established 
protocols (Schmidt et al., 2009). Tissues were fixed overnight at 4oC in modified 
Karnovsky’s fixative containing 3% glutaraldehyde and 1% paraformaldehyde in sodium 
cacodylate buffer pH 7.4. After rinsing in sodium cacodylate buffer, samples were 
postfixed in phophate cacodylate-buffered 21% OsO4 for 1h, dehydrated in graded 
ethanols with a final dehydration in propylene oxide and embedded in Embed-812 
(Electron Microscopy Sciences, Hatfield, PA). One-micron thick plastic sections were 
examined by light microscopy after staining with toluidine blue. Ultrathin sections (90 
nm thick) of individual samples were cut onto formvar coated slot grids, which permit 
visualization of larger cross sections. Sections were post stained with uranyl acetate and 
Venable’s lead citrate and viewed with a JEOL model 1200EX electron microscope 
(JEOL, Tokyo, Japan). Digital images were acquired using the AMT Advantage HR 
(Advanced Microscopy Techniques, Danvers, MA). Plastic sections as well as 
ultrastructural review was performed blinded to the genotype. 
Digitization and image analysis. Analyses were performed using an Olympus 
DP70 digital camera (Olympus, Tokyo, Japan) connected to an Olympus BX51 light 
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microscope or a Scanscope XT whole slide scanner/ImageScope v10.0.36.1805 (Aperio, 
Vista, CA). Image and pixel quantification employed established semiautomatic 
threshold algorithms (Lennerz et al., 2008) using the software package ImageJ 
[http://rsb.info.nih.gov/ij/; (Abramoff et al., 2004; Rasband, 1997-2007)]. Statistical 
testing between groups was performed using Student’s t-test and Wilcoxon two-sample 
test.    
Statistics. Chi-squared, t-tests (two tailed), the non-parametric alternative Mann-
Whitney U test, 1-way- and 2-way ANOVA, and Bonferroni post-tests to compare 
replicate means were used when appropriate. In experiments with small n’s (defined as 
n!12) the D’Agostino-Pearson omnibus K2 normality test (D'Agostino, 1986) was used 
to approximate Gaussian distribution of values. Therein P values of <0.05 indicate non-
Gaussian distribution and we assessed these experiments with both parametric and non-
parametric tests; both P values are provided when applicable. In all studies, the accepted 
level of significance was P<0.05 and data are reported as mean ± SEM. In selected 
experiments and for comparison between strains and experiments, values were 
normalized to the corresponding WT and errors were propagated according to the 
following formula: 
" [ (#x ?WT/x ?WT)2 + (#x ?KO/x ?KO)2 ]  . x?NKO  adapted after (Meyer, 1975) 
#x ? = standard error of the mean; x? = average; x?N = normalized average  
Error propagation and statistical tests in general were chosen assuming the most 
pessimistic situation (Rabinovich, 2000). All data were analyzed using Prism 5.0b 
(GraphPad Software Inc., La Jolla, CA) or Microsoft Excel 2008 (Version 12.1.9; 
Microsoft Corporation, Redmond WA). 
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Fig. 4.1 Targeted disruption of Par-1a in mice and tissue distribution of Par-1a and 
Par-1b.   
A. Par-1a locus (top), targeting vector (middle) and chromosomal organization after 
recombination (bottom). The Par-1a gene was disrupted by insertion of a neomycin (neo) 
phosphotransferase cDNA as a selectable marker. Sizes of upstream (2 kb) and 
downstream (3.8 kb) homologous arms are indicated (grey boxes), as is exon 2 (open 
box). Black boxes indicate positions of the probes for genomic Southern blotting; 
triangles depict locations of PCR primers for genotyping. Abbreviations: P=Pst I; B=Bgl 
II; S=Sac I; Hp=Hpa I; N=Nco I; H=Hind III.  B. Southern blot analysis demonstrating 
homologous recombination at the Par-1a locus. Genomic DNA was digested with Pst I 
and subjected to Southern blotting using the 5’ and 3’ probes indicated in panel A.  
Genotypes are indicated (WT: wild-type mouse; HET: heterozygous, KO: homozygous).  
C. PCR analysis of mouse DNA (tail), amplified with 3 PCR primers (a, b, and c) shown 
in panel A.  The WT-allele produces a 300 bp PCR product and null alleles produce a 400 
bp PCR product.  D. Western Blot analysis of Par-1a protein in brain lysates prepared 
from C57BL/6-mice.  E. Tissues from wild-type, Par-1a-/- and Par-1b-/- mice were 
isolated. Protein lysates from the indicated tissues were resolved by SDS-PAGE and 
subjected to Western blotting for the indicated proteins: Brain (0.2 mg), BAT=brown 
adipose tissue (1.1 mg), WAT=white adipose tissue (1.1 mg), colon (0.4 mg), 
Stom=stomach (0.4 mg), Thym=thymus (0.4 mg), Test=testis (0.4 mg), SPLN=spleen 
(0.4 mg), SKM=skeletal muscle (0.4 mg), Liver (0.13 mg), W=wild-type; K=knock-out. 
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Fig. 4.2 Par-1a-/--mice are growth retarded and hypermetabolic.  
A. Body weights of mice from birth to 30 weeks of age (n=4-14 per genotype per time 
point). B. Body weights at 6 and 20 weeks.  Body weights of Par-1a+/+- (black bars), 
Par-1a+/-- (striped bars), and Par-1a -/- (open bars) -mice at 6 weeks of age (number of 
animals per sex indicated).  C. Metabolic rate, D. energy expenditure, E. respiratory 
quotients (RQ=VCO2/VO2), and F. food intake in WT- (black bars) and Par-1a null mice 
(open bars).  G. Insulin tolerance tests were performed by i.p. injection of 0.30 unit/kg 
insulin into WT and Par-1a-/--mice (n as indicated); tail bleeds were obtained and 
glucose levels were monitored at indicated time points. Glucose levels plotted as % blood 
glucose at time 0 before injection. 
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Fig. 4.3 Resistance of Par-1a-/- mice to high-fat diet induced metabolic changes.   
A. Body weights during 15 weeks HFD starting at 3 weeks of age in male mice (n per 
genotype as indicated; P value designations: **, P<0.005; *, P<0.001).  B. Body weight 
gain (in %) indicated above weight comparisons of control group (black/white/grey) and 
HFD-arm of the trial (red) in 18-week-old male mice.  C. Glucose tolerance testing was 
performed by i.p. injection of D-glucose at 1mg/g body weight into all genotypes on 
chow and high-fat diet (n as indicated).  Glucose levels were monitored as indicated and 
expressed in % of initial glucose normalized to their littermates on chow; for comparison 
a dotted band shows the time course for WT and Par-1a-/- on chow diet. Statistical testing 
was performed using original values and P-values are provided for testing between 
genotypes on HFD (red) and between WT-HFD vs. WT-CD (black), when significant.  D. 
Serum insulin levels as determined by ELISA for the first 4 timepoints of the glucose 
tolerance test after HFD. 
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Fig. 4.4 Reduced adiposity and decreased glucose uptake in Par1a-/- mice.  
A. Tissues weights normalized to total body weight in indicated tissues from 18-week old 
male WT- (black bar) and Par-1a-/- -mice (open bars) fed with chow diet (black) or HFD 
(red; selected tissues); n!7 samples per tissue. Labeling a-e see results.  B. Hematoxylin 
and eosin (H&E) stain of WAT from Par-1a-/-- and Par-1a+/+-mice; insets, gonadal fat 
pads.  C. Weight comparisons of WAT between WT, Par-1a-/- and Par-1b-/--mice on 
chow (black, white, hatched, respectively) and after 16 weeks of high-fat diet (red); 
weights normalized to WT on chow diet.  Statistical tests and indicated P values derive 
from original weights (provided below bars).  D. Invasive biodistribution experiments 
following injection of 18F-FDG and dissection of gonadal WAT 1h post-injection; values 
expressed as % injected dose per gram of tissue (%ID/g).  E. H&E stain of BAT from 
Par-1a-/-- and Par-1a+/+-mice; insets, interscapular fat pads.  F. Weight comparisons of 
BAT between WT, Par-1a-/- and Par-1b-/--mice on chow (black, white, hatched, 
respectively) and after 16 weeks of high fat diet (red); weights normalized to WT on 
chow diet. Statistical tests and indicated P values derive from original weights (provided 
below bars).  G. Representative coronal section microPET images of 18F-FDG uptake in 
Par-1a-/-- (top) and Par-1b-/--mice (bottom) 1 h after 18F-FDG injection. 
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Fig. 4.5  Liver findings in high-fat diet- and starvation experiments.   
A. Morphologic comparison of Oil-red-O stained sections shows resistance to hepatic 
steatosis in Par-1a-/--mice. Inset: Abundant macrovesicular steatosis.  B. Semiautomated 
pixel quantification, expressed as percent of Oil-red-O-positive structures (fat) per high-
power field (HPF); genotypes, number of animal and diet indicated. C. Periodic acid 
Schiff (PAS) staining of liver of 20-week-old WT, Par-1a-/- and Par-1b-/- littermates 
following overnight fasting or 2 h after administration of 2 mg/g glucose by i.p. injection. 
Images are representative of 96 fields from 8 animals. D. WT-mice show a physiologic 
decreased in blood glucose in response to overnight starvation with a nadir at 24 + 4 h 
(top) and corresponding increased ketone production (bottom); note restoration of blood 
glucose and ketones, 2 h after intraperitoneal glucose injection (2 mg/g). Par-1a-/- mice 
show significantly lower blood glucose levels at both timepoints with associated 
hypoglycemia at 24 + 4 h.  Fasting hypoglycemia is accompanied by a significant 
decrease in ketone levels (hypoketotic hypoglycemia). Par-1b-/- mice maintained glucose 
levels and exhibited expected lower ketone levels. E. Glycogen content was measured in 
livers from 20-week-old Par-1a-/- (open bars), Par-1b-/-(grey bars), and WT (black bars) 
littermates following overnight fasting or 2 h after i.p. injection of 2 mg/g glucose. 
Tissues were extracted and acid hydrolyzed, and glycosyl units were assayed using an 
amyloglucosidase/glucose oxidase method (see Methods). F. Western Blot for glycogen 
synthase (GS) and phosphorylated GS (pGS) in overnight fasted liver samples of 4 
different animals per genotype; weight markers GS/pGS 100kDa (top), 75kDa (bottom); 
actin (37kDa); arrows indicate Par-1a-/- G. Ultrastructureal characterization of liver 
tissue from WT (a-c) and Par-1a-/- littermates (d-f) after nutrient starvation for 24 h.  Ga. 
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Toluidine blue-stained plastic section of starved WT liver at low magnification showing 
accumulation of lipid droplets (open arrow) and glycogen (arrow). Gb. Electron 
microscopic examination of WT hepatocytes at low-power magnification showing large 
number of variable-sized lipid vacuoles (open arrow) and glycogen islands (arrow). Gc. 
Detail of cytoplasmic organization with lipid droplets (open arrow) surrounded by 
numerous mitochondria (asterisks). Gd. Toluidin blue-stained plastic section of starved 
Par-1a-/- at low magnification shows absence of lipid droplets and glycogen. Ge. Electon 
microscopic examination of Par-1a-/- hepatocytes at low-power magnification showing 
absence of gycogen and lipid vacuoles. Gf. Detailed EM view of cytoplasmic 
organization with numerous autophagosomes (arrows) consisting of isolated membranes 
surrounding cytosolic material (top: so-called myelin figures; bottom ingested rough 
endoplasmic reticulum). Note the close proximity of autophagocytic vacuoles and 
mitochondria (asterisk). 
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Fig. 4.6 Par-1b-/-/Par-1a-/--double knock-out mice are not viable and breeding 
experiments support ranked redundancy between isoforms.   
A. Survival analysis of the offspring from matings of double-heterozygous Par-1a/b 
mutant mice.  The black bars plot the observed frequency of the indicated genotypes as 
percentage of the total, whereas the gray background indicates the expected frequency 
based on Mendelian inheritance (n=2466).  B. Comparison of body weights for five of 
the obtained genotypes from B. Weight is normalized to WT-littermates [HK, n=6 mice 
at 15-20 weeks vs. control WT (n=6); KH (E17dpc) n=12 vs. age-matched control WT 
(n=8; from same litter)]. 
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Table 4.1  Multifunctionality of Par-1-Polarity Kinase Pathways 
 
A. Regulators    Function (‘upstream’)    Reference 
LKB1  Wnt-signaling; Peutz-Jeghers syndrome, Insulin signal transduction, pattern formation (Alessi, 2001; 
Lizcano et al., 2004; Spicer et al., 2003) 
TAO1  MEK3/p38 stress-responsive mitogen-activated protein (MAP) kinase pathway             (Hutchison et al., 1998) 
MARKK  Nerve growth factor signaling in neurite development and differentiation  (Timm et al., 2003) 
aPKC  Ca2+/DAG-independent signal transduction, cell polarity, glucose metabolism  (Brajenovic et al., 
2004; Goransson et al., 2006; He et al., 2009; Hurov et al., 2004; Kusakabe and Nishida, 2004; Ossipova et al., 2005; Suzuki et al., 
2004) 
nPKC/PKD  DAG-dependent, Ca2+-independent signal transduction (GPCR)                                   (Watkins et al., 2008)  
PAR-3/PAR-6/aPKC (-) regulates Par-1; assembly of microtubules, axon-dendrite specification                   (Chen et al., 2006) 
GSK3!    (-) tau-phosphorylation; Alzheimer’s dementia; energy metabolism, body patterning         (Kosuga et al., 2005; 
Timm et al., 2008) 
Pim-1 oncogene (-) G2/M checkpoint; effector of cytokine signaling and Jak/STAT(3/5)                           (Bachmann et al., 2004)  
CaMKI   (-) Ca2+-dependent signal transduction; neuronal differentiation                                     (Uboha et al., 2007)  
 
B. Substrates                Function (‘downstream’)    Reference 
Cdc25C   Regulation of mitotic entry by activation of the cdc2-cyclin B complex  (Dalal et al., 1999; 
Ogg et al., 1994; Peng et al., 1998; Zhang et al., 1997)  
Class II HDAC  Control of gene expression and master regulator of subcellular trafficking                          (Dequiedt et al., 2006; 
Kao et al., 2001) 
CRTC2/TORC2 Gluconeogenesis regulator via LKB1/AMPK/TORC2 signaling, PPAR"1a coactivator        (Jansson et al., 2008) 
Dlg/PSD-95 Synaptogenesis and neuromuscular junction; tumor suppressor                                                (Woods and Bryant, 
1991)(Zhang et al., 2007) 
Disheveled  Wnt-signaling; translocation of Dsh from cytoplasmic vesicles to cortex            (Ossipova et al., 2005; Sun et al., 
2001) 
KSR1   Regulation of the Ras-MAPK pathway                           (Muller et al., 2001; Muller et al., 2003)  
MAP2/4/TAU ‘Dynamic instability’ (Mitchison and Kirschner, 1984; Sammak and Borisy, 1988) of microtubules; 
Alzheimer’s dementia (Drewes, 2004) (Biernat et al., 2002; Drewes et al., 1998; Drewes et al., 1997; Drewes et al., 1995; Illenberger 
et al., 1996; Murphy et al., 2007; Tian and Deng, 2009) 
Mib/Notch Mind bomb (Mib) degradation and repression of Notch signaling = neurogenesis (Krahn and Wodarz, 
2009; Ossipova et al., 2005; Rubio-Aliaga et al., 2007)  
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Par3/OSKAR/Lgl Cytoplasmic protein segregation, cell polarity and asymmetric cell division  (Benton et al., 2002; 
Betschinger et al., 2003) 
Pkp2  Desmosome assembly and organization; nuclear shuttling                       (Muller et al., 2001; Muller et al., 2003) 
PTPH1   Linkage between Ser-/Thr- and Tyr-phosphorylation dependent signaling                    (Zhang et al., 1997) 
Rab11-FIP  Regulation of endocytosis (Cullis et al., 2002); trafficking of E-cadherin                         (Ducharme et al., 2006) 
LKB1 also known as Par-4; MARKK also known as Ste20-like; (-): inhibitory/negative regulation has been 
shown; GPCR: G-protein coupled receptors; MARKK is highly homologous to the thousand and one amino 
acid kinase (TAO-1) (Hutchison et al., 1998) 
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Table 4.2  Terminology and Localization of the Mammalian Par-1 Family Members 
  Synonyms                     Subcellular localization 
 Par-1a, MARK3, C-TAK1, p78/KP78, 1600015G02Rik,  
     A430080F22Rik, Emk2, ETK-1, KIAA4230,             basolateral1/apical2 
     mKIAA1860, mKIAA4230, M80359      
 Par-1b, EMK, MARK2, AU024026, mKIAA4207                   basolateral 
 Par1c, MARK1                     basolateral 
 Par1d, MARK4, MARKL1             not asymmetric3  
Par: partitioning defective [not to be confused with protease-activated receptor 1 (PAR1; 
(Di Serio et al., 2007)]; C-TAK1: Cdc twenty-five C-associated kinase 1; MARK: 
microtubule affinity regulating kinase; MARKL: MAP/microtubule affinity-regulating 
kinase like 1; 1to a lesser degree in comparison to Par-1b (Goransson et al., 2006); 
2human KP78 is asymmetrically localized to the apical surface epithelial cells (Parsa, 
1988); 3variant that does not show asymmetric localization in epithelial cells when 
overexpressed (Suzuki et al., 2004). 
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Table 4.3 Metabolic characteristics of Wild-type (WT), Par-1a-/- and Par-1b-/- 
animals. 
 
 
Twenty-week-old mice on regular chow diet were fasted overnight (n!11 per genotype; 
all male, unless otherwise indicated); serum values are expressed as the mean ± SEM of 
measurements obtained. P represents P value of Student’s t tests comparing Par-1 mice 
with WT (asterisk indicates significance). $indicates significantly lower adiponectin 
levels in male mice (P=0.0003); note: this gender difference is lost in both Par-1 mice; 
NEFA: non-esterified fatty acids. 
 
 
 
 
 
 
 
 
        
 Insulin Glucagon Leptin Adiponectin Triglyceride
s 
Cholesterol NEFA 
 ng/ml pg/ml ng/ml µg/ml mg/dl mg/dl µmol/liter 
         
         
    Male Female    
WT 0.65 ± 
0.10 
 45.5 ± 
11.7 
3.68 ± 
0.26 
9.8 ± 0.66$ 17.9 ± 1.7 74.9 ± 3.46 83.27 ± 2.4  1303 ± 
65.8 
         
Par-1a-
/- 
0.61 ± 
0.08 
31 ± 4.33 3.64 ± 
0.16 
16.5 ± 1.6 18.4 ± 2.2 73.1 ± 3.77 74.95 ± 
2.87 
1329 ± 107 
P= 0.74 0.27 0.79 0.0008* 0.87 0.74 0.03* 0.84 
         
Par-1b-
/- 
0.37 ± 
0.04 
34 ± 2.25 3.02 ± 
0.16 
11.4 ± 1.3 11.7 ± 
0.84 
62.2 ± 3.39 73.45 ± 
2.81 
1149 ± 66.3 
P= 0.04 0.39 0.16 0.28 0.005* 0.013* 0.011* 0.11 
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Fig. 4.S1  UCP2 and LC3 protein levels in livers from mice on high fat diet and 
overnight starvation. 
Western blot for UCP2 (A.) and LC3 (B.) in overnight fasted liver samples of four 
different animals per genotype. Weight markers: UCP2, 30kDa; LC3, 15 kDa; actin, 
37 kDa. 
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Summary 
 Establishing and maintaining cellular polarity are critical for the homeostasis of 
unicellular and multicellular organisms.  The major goal of my thesis work was to 
investigate functional interactions between the Par-1b protein kinase and the RNF41 E3 
ubiquitin ligase.  Atypical Protein Kinase C (aPKC) phosphorylates Par-1b on a 
conserved threonine residue (T595), and I participated in studies demonstrating that novel 
Protein Kinase C (nPKC) activates Protein Kinase D (PKD) to directly phosphorylate 
Par-1b on serine 400 (S400), a residue that is conserved in all four mammalian Par-1 
kinases as well as the fly ortholog.  Phosphorylation of Par-1b on T595 and S400 causes 
Par-1b to relocate from membranes to the cytosol and to bind 14-3-3 proteins.  In 2004, 
Brajenovic, et al. isolated human Par-1d along with associated proteins using tandem 
affinity purification (TAP) (Brajenovic et al., 2004).  Nrdp1/RNF41, a RING finger E3 
ligase was identified in their screen along with 14-3-3 and aPKC.  I found that Par-1b 
also binds to RNF41 and identified RNF41 as a novel cell polarity determinant.  I also 
showed that Par-1b phosphorylates RNF41 on S254 both in vitro and in vivo.  My work 
has demonstrated that phosphorylation of RNF41 on S254 by Par-1b is necessary for 
establishing epithelial apical-basal cell polarity. 
 
Discussion 
Cell polarity is a structural and functional specialization whose significance is 
ubiquitous throughout biology.  It is especially common across phyla, thus reflecting a 
fundamental requirement to localize different cellular components to distinct regions of a 
cell, especially when individual cells come together to form complex multicellular tissues.  
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The specialized domains of plasma membrane that result from polarization determine cell 
orientation, function, and fate.  For example, cell polarization enables long-range 
communication in the immune system, transport of ions across epithelial cells, and niche-
specific orientation of stem-cell division, which specifies the developmental fate of 
daughter cells (Mellman and Nelson, 2008).   
 Par-1b/MARK2 is essential in the establishment of polarity.  In the early C. 
elegans embryo, mutation of Par-1, among several other partitioning proteins, disrupts 
asymmetric divisions, blastomere fates, localization of P granules, and mitotic spindle 
orientation (Kemphues et al., 1988; Kirby et al., 1990).  Some Par-1 mutants have 
mutations in their kinase domain, suggesting that kinase activity of Par-1 is necessary to 
establish polarity (Guo and Kemphues, 1995).  Additionally overexpression of Par-
1b/MARK2 in MDCK cells inhibits apical-basolateral polarization by altering apical 
protein transport (Cohen and Musch, 2003).   
 My thesis work has helped identify and investigate a new phosphorylation site 
(S400) on Par-1b (Watkins et al., 2008).  This work demonstrated that phosphorylation 
on S400 is upregulated with the PKC activator phorbol-12-myristate-13-acetate (PMA) 
stimulation.  PMA activates nPKC, which then phosphorylates PKD.  PKD subsequently 
phosphorylates Par-1b on S400.  Par-1b is phosphorylated through two arms of the PKC 
pathway on T595 and S400 and phosphorylation regulates Par-1b localization and 
binding to cytoplasmic 14-3-3/Par-5 proteins (Hurov et al., 2004; Watkins et al., 2008).  
Moreover, our studies using polarized breast epithelial cells (MCF-10A) grown in three-
dimensional (3D) culture, we observed enhanced phosphorylation of Par-1b on both S400 
and T595 in 3D cultures relative to the two dimensional (2D) cultures.  In the future it 
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would be critical to test if phosphorylation of Par-1b on S400 and T595 are essential for 
establishing apical/basal epithelial cell polarity or if phosphorylation of Par-1b on S400 
and T595 is a result of established cell polarity. 
Another goal of my thesis project was to study the Par-1b and RNF41 protein-
protein interaction.  I identified a new Par-1b substrate, the E3 ubiquitin ligase RNF41 
and demonstrated that Par-1b phosphorylates RNF41 both in vivo and in vitro on S254.  
Knockdown of RNF41 in MCF-10A breast epithelial cells using shRNA revealed a novel 
role for RNF41 as being essential for establishing apical-basal cell polarity.  Moreover, 
expression of wild-type RNF41 in these cells rescued apical-basal polarity; however, 
expression of the S254A mutant of RNF41 was not able to do so, suggesting that 
phosphorylation on S254 is necessary for establishing apical-basal cell polarity and 
continuing the theme of phosphorylation regulating polarity proteins.  Interestingly, 
orthologs of every Par gene, except the RING finger containing Par-2, have been 
identified in mammals.  Par-2 functions to regulate and stabilize cell polarity in C. 
elegans and shares homology with RNF41 in their RING finger domain and part of their 
C-terminal domain, leaving open the interesting possibility that RNF41 is an ortholog of 
Par-2.    
We were unable to detect phosphorylation of endogenous RNF41 on S254 when 
cells were grown in 2D cultures.  Given the critical role played by Par proteins in 
establishing and maintaining apical-basal polarity, we investigated the phosphorylation 
status of RNF41 in MCF-10A mammary epithelial cells grown in 3D culture and 
observed enhanced phosphorylation on endogenous RNF41 S254.  The observation that 
cells polarized in 3D culture illustrated the link between phosphorylation of RNF41 on 
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S254 and establishment of epithelial cell polarity.  Furthermore, this observation 
emphasizes the importance and influence of the cell microenvironment, since cellular 
context clearly can modulate Par protein function.  Another example of this is seen with 
Par-6 and aPKC, as both of these proteins are concentrated at tight junctions of epithelial 
cells grown in 2D cultures, but are spread over the apical surface in 3D cultures.  Within 
the much more complicated environment of an organism, such influences are likely to be 
widespread and might alter signaling inputs to and outputs from the polarity regulating 
proteins such as Par-1 and RNF41. 
Cells can adopt different functions in response to specific physiological contexts, 
and the plasticity of the loss and re-establishment of cell polarity suggests that common 
mechanisms are used but executed differently depending on the physiological context.  In 
disease states such as metastatic cancers, epithelial cells lose polarity (one way is through 
epithelial-mesenchymal transition (EMT)), disengage from multicellular interactions, 
migrate, and then reintegrate into a second tissue, in which they undergo reorganization 
to reside at the new site (Thiery and Sleeman, 2006; Wodarz and Nathke, 2007).  Cells 
expressing RNF41 shRNA with and without expression of the S254A mutant of RNF41 
do not express the classical protein markers for EMT (low E-cadherin and high Vimentin 
and SNAIL protein levels); however, these cells may be undergoing a partial EMT and 
warrant further examination since we have observed that these cells are not able to 
establish apical-basal polarity in 3D culture.   
RNF41 has been studied for its role as an E3 ubiquitin ligase in regulating steady 
state neuregulin receptor ErbB3 levels (Diamonti et al., 2002).  ErbB3 is overexpressed in 
a subset of breast cancers.  Moreover, there is a correlation seen between decreased 
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RNF41 levels and higher levels of ErbB3 in both an in vivo transgenic mouse model of 
ErbB2-induced mammary tumorigenesis and in a panel of primary breast tumors (Yen et 
al., 2006).  While one mechanism for proliferation and establishment of these tumors may 
be due to increased levels of ErbB3, loss of RNF41 and thus lack of cell polarity, may 
also contribute to this process.  
Over 85% of fatal malignancies in adults in the USA arise from epithelial tissues 
(Bryant and Mostov, 2008), and loss of polarity is a hallmark of increased malignancy.  
Furthermore, acute injury of major epithelial organ systems is collectively one of the 
most important causes of death worldwide (Fausto et al., 2006; Liano and Pascual, 1996; 
Matthay and Zimmerman, 2005).  Understanding polarization of epithelia, therefore, is 
important in analyzing the response of a tissue to injury and in establishing prospects for 
regenerative medicine.  Many organs, such as the kidney, lung, and liver, can recover 
from injury.  In the case of the kidney, this involves the local proliferation of epithelial 
cells which replace their dead neighbors in a process that involves partial EMT (Bryant 
and Mostov, 2008).  Learning how to improve the response to injury by controlling the 
polarity state of cells offers enormous possibilities to enhance human health. 
Understanding cell polarization is one of the major goals of cell biology and will 
inevitably have a broad impact not only at the level of basic science but also in 
understanding diseases such as cancer.  Work from many laboratories has uncovered a 
complicated web of signaling systems that surround and intersect with the Par proteins, 
yet we still understand very little about what the Par proteins do, how they are localized, 
how their various interactions are regulated, and which signaling components operate in 
which contexts.  After all, the organization of a polarized cell is a complicated process 
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that involves cytoskeletal remodeling, membrane traffic, and protein complex assembly 
and disassembly, with feedback to gene expression and protein turnover. 
Future Directions 
 The C-terminus of RNF41 binds to the Rhodanese domain of USP8 (the enzyme 
which deubiquitinates and thus stabilizes RNF41 protein) and the crystal structure of this 
heterodimer has previously been published (Avvakumov et al., 2006).  After examining 
the crystal structure of the USP8 binding pocket on the C-terminus of RNF41, we noticed 
that S254 on RNF41 resides in this pocket and hypothesize that phosphorylation on S254 
may affect USP8 binding.  Therefore, I will immunoprecipitate wild-type and the S254A 
mutant of RNF41-FlagHis6 from MCF-10A cells grown in 3D culture, and I will Western 
blot for USP8 in order to compare the levels of binding of USP8 to RNF41.  I 
hypothesize that phosphorylated RNF41 may bind less USP8 than wild-type or the 
S254A mutant.  If this is true, then the levels of phosphorylated RNF41 should be lower 
than the non-phosphorylated form.  However, if the S254A mutant of RNF41 prevents 
phosphorylation and still binds to USP8, then its protein levels should be higher than 
wild-type RNF41.  An alternative hypothesis is that phosphorylated RNF41 may bind 
more USP8 than wild-type or the S254A mutant of RNF41.  If this is the case, then the 
phosphorylated form of RNF41 should be stabilized and the S254A mutant of RNF41 
should bind less USP8, and therefore its levels should be lower than the phosphorylated 
form of RNF41.  
 During my thesis work I have shown that Par-1b binds and phosphorylates 
RNF41 on S254 in vitro.  Furthermore, RNF41 is phosphorylated on S254 in vivo and 
overexpression of kinase active Par-1b enhances this phosphorylation in vivo while 
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kinase dead Par-1b does not.  I have generated MCF-10A cells which stably express two 
separate shRNA hairpins for human Par-1b and have shown that Par-1b protein levels are 
reduced by greater than 90% in these cells.  Thus, I will culture these cells in 3D and 
subsequently Western blot for pS254 RNF41.  I hypothesize that pS254 RNF41 levels 
will decrease in these cells compared to pS254 levels in control MCF-10A cells; however, 
it is possible that I may not detect a decrease in the level of pS254 RNF41 due to 
compensation by other mammalian Par-1 orthologs.  We know from our study and from 
work by others that both Par-1b and Par-1d bind to RNF41 (Brajenovic et al., 2004).  
Thus, it is possible that other mammalian Par-1 proteins may also bind to RNF41 and 
there likely may be some compensation by these other Par-1 proteins when Par-1b is 
depleted in cells. 
 After examining our work with Par-1b and RNF41, still the question remains, 
how does RNF41 regulate apical-basal cell polarity?  Recently, work by others has shown 
that Par-1b kinase activity and protein localization is essential for regulating basement 
membrane placement.  Furthermore, this study also showed that establishment of the 
correct localization of basement membrane is required for the coordination of tissue 
polarity (Daley et al, 2012.).  Epithelial cell organization and function require positional 
information from the surrounding microenvironment (Bryant and Mostov, 2008); such 
cues include contacts with both adjacent cells and the basement membrane.  I have 
preliminary data which suggests that loss of RNF41 results in the loss of Laminin V 
deposition (basement membrane) on the cell surface of the MCF-10A acini where it is 
needed to establish apical-basal polarity.  Moreover, Laminin V accumulation is rescued 
when wild-type RNF41 is overexpressed; however, not when cells are rescued with the 
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S254A mutant of RNF41 suggesting that phosphorylation of RNF41 on S254 is necessary 
for Laminin V deposition.  In the future, I will test if accumulation of other basement 
membrane proteins (such as collagen IV, fibronectin, and perlecan) is affected by the loss 
of RNF41.  This will be determined by Western blot, immunofluorescence microscopy, 
and qPCR for basement membrane proteins and genes.  I hypothesize that the loss of 
apical-basal polarity observed in cells expressing RNF41 shRNA is due to the loss of 
endogenous basement membrane accumulation.  Thus, I will culture the MCF-10A cell 
lines expressing Luc shRNA, RNF41 shRNA, RNF41 shRNA + wild-type RNF41, or 
RNF41 shRNA + S254A RNF41 in 3D culture using Matrigel instead of collagen type I 
and stain for apical and basal polarity markers in order to determine if apical-basal 
polarity is rescued when these cells are supplemented with exogenous basement 
membrane proteins. 
 Another possible explanation for the lack of established apical-basal cell polarity 
in cells expressing RNF41 shRNA and the S254A mutant of RNF41 is that S254A 
RNF41 is mislocalized.  Preliminary data indicates that wild-type RNF41 overexpressed 
in MCF-10A cells cultured in collagen type I matrix is localized to basolateral 
membranes; however, the S254A mutant of RNF41 is mislocalized and accumulates in 
the cytoplasm.  Future experiments will also be directed at determining if S254 
phosphorylation regulates the intracellular localization of RNF41. The failure of the 
S254A mutant of RNF41 to localize properly or to bind to key substrates would account 
for its failure to rescue polarity in RNF41 deficient MCF-10A cells.  
Finally, in the future I propose to determine how RNF41 regulates basement 
membrane (Laminin V) deposition.  Previous work has demonstrated that Par-1b kinase 
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activity is essential for cell surface assembly of laminins by regulating one of the laminin 
receptors, the dystroglycan (DG) complex (Masuda-Hirata et al., 2009).  I propose to 
investigate if RNF41 plays a role in laminin receptor assembly and/or function in order to 
regulate basement membrane accumulation on the cell surface.  Determining how RNF41 
regulates cell polarity and basement membrane deposition is critical for numerous 
reasons; however, one implication may be in cancer as loss of apical-basal polarity is a 
characteristic of tumor cells.  Also, RNF41 protein levels have previously been shown to 
be low in some breast cancers.  Preliminary data suggests that low RNF41 protein levels 
results in loss of basement membrane proteins; thus one might hypothesize that without 
basement membrane tumor cells not only are incapable of establishing apical-basal 
polarity, but may also be more likely to escape and metastasize.    
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